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resumo 
 
 
O envelhecimento é definido como um processo fisiológico complexo 
acompanhado de um declínio progressivo das estruturas biológica, psicológica 
e social dos indivíduos. A análise de metabolitos é cada vez mais utilizada em 
diversos estudos da população humana, com a finalidade de compreender os 
processos fisiológico e patológico do indivíduo. Sabe-se que o crescente 
envelhecimento da população é a origem de enormes desafios nos cuidados 
de saúde e no tratamento de doenças relacionadas com a idade, sendo o 
"envelhecimento" um campo de pesquisa promissória. O metaboloma humano 
varia ao longo da vida e essas alterações estão possivelmente relacionadas 
com o aparecimento de várias doenças associadas à idade, sendo expectável 
que o estudo do metaboloma do envelhecimento possa contribuir para a 
compreensão da sua fisiologia molecular e das doenças relacionadas com 
este. A utilização de técnicas de análise metabolómica, como o FTIR, pode 
ajudar a identificar quais os preditores biológicos do envelhecimento, 
contribuindo para a compreensão dos mecanismos envolvidos no seu 
processo. O FTIR é uma técnica que tem recebido especial atenção no campo 
clínico, uma vez que utiliza as frequências de vibração das ligações químicas 
das moléculas presentes nas várias amostras analisadas para a obtenção de 
uma “impressão digital” metabólica específica para cada amostra de forma 
rápida e barata. 
Esta dissertação tem como objetivo identificar as diferenças ao nível das 
proteínas e agregados proteicos presentes em diferentes amostras através da 
aplicação do FTIR na região do infravermelho médio. 
Numa primeira abordagem, a técnica de FTIR foi aplicada a amostras de 
leveduras de forma a identificar alterações nas proteínas. Foram ainda 
aplicadas metodologias de análise multivariada (PCA e PLS) com o objetivo de 
distinguir, ao nível das proteínas, amostras de leveduras wild-type e stress 
(com indução de agregados). Como a técnica de FTIR demostrou ser capaz de 
identificar alterações proteicas em amostras de levedura foram usadas 
amostras de plasma humano de indivíduos compreendidos entre os 65 e 82 
anos de idade. Recorrendo à mesma metodologia estudaram-se amostras de 
plasma de indivíduos com diferentes idades, pretendendo-se relacionar a 
idade com a presença de agregados proteicos/alteração da conformação 
proteica.  
Os espectros compreendem um vasto conjunto de comprimentos de onda, no 
entanto, apenas a região 1800-1350 cm
-1
 foi alvo de um maior estudo, visto 
que está maioritariamente relacionada com a conformação das proteínas e 
com a presença de agregados proteicos.  
A técnica de FTIR tornou-se um método promissor de screening, uma vez que 
demonstrou ser uma técnica capaz de contribuir para a compreensão do 
processo de envelhecimento. 
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abstract 
 
 
Aging is defined as a complex physiological process accompanied by a 
progressive decline of biological, psychological and social structures of 
individuals. Metabolite analysis is being used in several studies of human 
populations in order to understand physiological and pathologic processes of 
an individual. It is known that the increasing aging of population is the origin of 
enormous challenges to healthcare provision and treatment of age-related 
diseases, being "aging" a promissory research field. Human metabolome 
varies throughout life and those changes are certainly related to the onset of 
several age-related diseases. It is expectable that the study of aging 
metabolome could help to understand molecular physiology of aging and age-
related diseases. The use of metabolic analysis techniques, such as FTIR, may 
help to identify the biological predictors of aging, which allow understanding the 
mechanisms involved in the aging process. FTIR technique has received 
special attention in the clinical field, once it uses the vibration frequencies of 
the chemical bonds of molecules present in the analyzed sample to yield a 
metabolic fingerprint specific for each molecule quickly and cheaply. 
This dissertation pretends to identify the differences at the protein level and 
protein aggregates in different samples, through the application of FTIR 
spectroscopy in the medium infrared region. 
In a first approach, the FTIR technique was applied to yeast samples in order 
to identify protein alterations. Multivariate data analysis methodologies (PCA 
and PLS) were also applied in order to distinguish, at the protein level, wild-
type and stress (with aggregate induction) yeast samples. FTIR technique has 
been shown to be capable of identifying protein changes in yeast samples, so 
human plasma samples from individuals between 65 and 82 years old were 
used. Using the same methodology, plasma samples from individuals of 
different ages were studied, with the goal to relate age with the presence of 
protein aggregates/alteration of protein conformation. 
The spectra comprise a wide set of wavelengths, however, only the 1800-1350 
cm
-1
 region of the spectrum received larger study, once it is mostly related with 
protein conformation and with the presence of protein aggregates. 
The FTIR technique has become a promising screening method, since it has 
shown to be a technique capable of contributing to the comprehension of the 
aging process. 
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Chapter One 
This chapter defines and characterizes aging and summarizes its main theories and 
senescence mechanisms. Also, clarifies the importance of aging biomarkers, describes the 
hallmarks of aging and identified biological predictors of aging. An introduction of the 
Fourier Transform Infrared spectroscopy technique as novel diagnostic modality of aging 
is also made. The aims of the work are presented in the final part of the chapter. 
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1. INTRODUCTION 
Aging is defined as a complex physiological process characterized by a persistent decline in 
the age-specific fitness components of an organism due to internal physiological deterioration [1]. 
It is mainly caused by genetic and environmental influences such as diet, physical exercise, 
exposure to pollutants and microorganisms: these factors explain how two people with the same 
chronological age differ widely in their physical appearance and physiological state [2]. Some of 
the consequences of aging process are loss of mobility and agility, weakness, end of the 
reproductive capacity and debility of the immune system – immunosenescence – which implies 
higher vulnerability for cancer, autoimmune diseases or infections and neurodegeneration [3–5]. 
Instead of prolonging lifespan at all costs it is vital to have an increased healthspan, the portion of 
lifespan throughout which function is satisfactory to preserve autonomy, productivity and well-
being. Due to the increasing aging population, the healthcare has to surpass several challenges 
[6]. Therefore aging biomarkers (AB) are an urgent need to measure the health state of elderly 
and assess the effect of novel treatments and it is essential too, once it will be beneficial to 
determinate the biological age [7].  
This work aims to systematically review the biological predictors of aging that can be useful 
to interpret and extract the information obtained by metabolomic assays. The potential of FTIR as 
a metabolic tool to contribute to aging metabolic fingerprint is also discussed. 
 
2. THEORIES OF AGING 
The enigmatic nature of aging makes its study one of the greatest challenges of science. 
Despite advances in biological knowledge and molecular approaches to analyze biological 
samples, the exact answer to the biggest questions: why and how organisms age are still 
unknown. Over the decades many theories have emerged to describe aging. For instance, 
Medvedev catalogued about 300 and the number is still growing [8,9]. 
 
2.1. Evolutionary Theories of Aging 
The oldest arguments about the evolution of aging were written in 1858 by Darwin & Wallace 
and were related with natural selection [10]. However it was August Weismann who debated for 
the first time the problem about how aging evolved [11] and created the first evolutionary theory 
of senescence - the theory of programmed death - based on natural selection [12]. This theory 
proposes that aging leads to the improvement of the species and not the individual. According to 
this theory, there is an exact mechanism of death projected by natural selection to remove older 
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individuals therefore they would no longer compete with the younger generations. The biological 
mechanism of this theory is explained by the existence of a precise limitation on the number of 
divisions in somatic cells [12,13]. This speculation was confirmed by Hayflick and Moorhead in 
1961 [14], when they found that fibroblasts have a limited number of cell divisions. However, 
Weismann abandoned this theory later, considering that organisms should be able to apply 
further resources to reproduce [13]. Based on this idea, Thomas Kirkwood created the disposable 
soma theory suggesting that the somatic cells are preserved only to guarantee the success of 
reproduction process, becoming disposable after this period [15], and foresees that aging arises 
due to the increasing of cellular damages [16].  
Later, Peter Medawar, a British professor of zoology and anatomy, proposed the mutation 
accumulation theory of aging. He hypothesized that if a deleterious mutation was limited to long-
lived organisms, this will be passed to the next generation before the prejudicial effect of it 
becomes evident [13,17,18]. Finally, the antagonistic pleiotropy theory of aging was created by 
George C. Williams and he suggested that senescence and cellular damage are the consequence 
of pleiotropic genes or genes with several phenotypic effects and that natural selection selects 
genes that increase the probabilities of success in early life regardless of those genes have 
harmful effects in later life [19,20]. 
 
2.2. Senescent Theories of Aging 
The evolutionary theories of aging explain why we age but the mechanisms of senescence 
give us the answer to how we age and how aging disturbs homeostasis. These mechanisms are 
generally controversial and some of them have more credibility than others but all have scientific 
validation [8,21]. 
In 1956 Harman proposed the free radical theory [22], that considers that aging is a result of 
the ineffectiveness of the antioxidant systems. About 90% of reactive oxygen species (ROS) (O2, 
O2
- and OH) are produced in mitochondria through oxidative phosphorylation [23]. In 1963 Leslie 
Orgel [24] suggested the error catastrophe theory, describing that aging causes a decline in 
fidelity of genetic expression leading to errors in protein synthesis. Errors in mRNA and/or 
proteins would compromise the balance of the cell. Most of these accumulated genes are 
eliminated by repair systems, but occasionally it does not function properly, causing an 
accumulation of genomic errors [25]. Two years later, in 1965, Hayflick created the telomere 
theory [26]. Telomeres are repetitive DNA sequences located at the end of each human 
chromosome. In every cell division, telomeres become increasingly shorter, once replicative DNA 
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polymerases are not capable of replicating telomeres and telomerase is typically expressed in 
germ cells and only in some adult stem cells. Sooner or later the cell finishes growing and gets into 
senescence [25,27]. Later, in 1970, Kanungo proposed the gene regulation theory (reviewed in 
[28]). It defines that differentiation, growth, maturity and senescence have their own regulation 
mechanisms. The products/sub-products of each phase can trigger the following phase by 
activating or repressing specific genes. So, senescence is the consequence from alterations in 
gene expression with aging [28]. In 1972, Harman described the function of free radicals in 
mitochondrial damage creating the mitochondrial theory [22,29]. Mutations in mitochondrial DNA 
(mtDNA) lead to a decrease on oxidative phosphorylation, decreasing the production of energy 
and consequently increasing ROS [25,29]. Fabris, one of the researchers studying the relation 
between immune, neurological and endocrine systems and aging created the immune-neuro-
endocrine theory in 1990, which proposes that the loss of plasticity between immune and 
neuroendocrine systems leads to aging. This theory is based on the existence of a functional 
decline of immune system and a growth of autoimmune factors [30,31]. Finally, in 2009, Chung et 
al., related inflammation and aging, creating the inflammation theory [32]. During aging there is a 
dysregulation of the immune system and a modification of the redox status. The inflammatory 
mechanism is associated to aging and age-related diseases (ARD) and it works like a linkage 
among normal and pathological aging. The upregulation of pro-inflammatory intermediaries 
which are activated by aging due a redox imbalance leads to activation of different pro-
inflammatory signaling pathways [32]. 
 
3. THE HALLMARKS OF AGING 
Aging is caused largely by accumulation of cellular damage. Some pathologies associated 
with aging, like inflammation and atherosclerosis, imply uncontrolled cellular growth or 
hyperactivity [33]. Based on these, a few critical questions have amounted about the physiological 
bases of aging. López-Otín et al., 2013 identified and characterized nine cellular and molecular 
hallmarks of aging which contribute to the aging process and that all together define the aging 
phenotype [34]. 
Each one of the nine hallmarks must satisfy the ensuing criteria: (1) should be evident in 
normal aging; (2) experimental aggravation must hasten aging and (3) experimental improvement 
should delay the normal aging process and consequently increase healthy lifespan. These nine 
hallmarks of aging are distributed in three categories: primary hallmarks, antagonistic hallmarks 
and integrative hallmarks [34] (figure 1). 
6 
 
The primary hallmarks have in common the fact that are all clearly harmful. One of the 
primary hallmarks of aging is telomere attrition. The progression of cell divisions takes to attrition 
of chromosomes ends [9,35,36]. When the telomeres reach a certain short length, cell senescence 
is triggered, known as replicative senescence, linked to telomere attrition [36,37]. During aging 
there is also a lot of genetic and epigenetic alterations that are responsible to regulate lifespan, as 
well as a decrease in protein homeostasis, which is responsible for some age-related diseases 
[38]. The consequences from extrinsic and intrinsic DNA damage include translocations, point 
mutations, chromosomal losses and gains and telomere shortening. It is also known that defects 
in nuclear architecture lead to genome instability and result in premature aging syndromes 
[34,39–42].  
 
Figure 1 - The nine suggested hallmarks of aging grouped into three categories: primary hallmarks, 
responsible for cellular damage; antagonistic hallmarks, which are part of compensatory or antagonistic 
answers to the damage and integrative hallmarks, which firstly mitigate the damage, but become 
deleterious if aggravated. The relation between these hallmarks characterize to the functional decline 
related with aging. Adapted from [34]. 
 
Antagonistic hallmarks have contradictory effects based on their intensity once at low levels 
they lead to beneficial effects. In this class of hallmarks it is possible to consider mitochondrial 
dysfunction, deregulated nutrient sensing and cellular senescence. Aging is related with the 
accumulation of somatic mitochondrial DNA mutations and also the aging process is characterized 
by severe metabolically alterations in the body. In the period of food plenty, nutrient sensing 
pathways involve anabolism and storage, and scarcity activates homeostatic mechanisms, such 
the mobilization of internal stores through autophagy for example [43]. Nutrient and stress 
sensors intervene in extend lifespan that happen in response to various physiological and 
environmental signals such as dietary restriction which is responsible for a rapid decrease in the 
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mortality rate, neutralizing the causes of aging in an acute way [44]. During aging there is an 
irreversible arrest of cell proliferation, known as cellular senescence [34]. This antagonistic 
hallmark of aging can be an advantageous compensatory response to the damages which become 
deleterious and accelerate aging when tissues deplete their regenerative capability [34]. 
The third category, integrative hallmarks, comprises stem cell exhaustion and altered 
intercellular communication which affect homeostasis [34]. These hallmarks are all interrelated, 
however there are still many challenges in comprehending the aging process [34,45]. Adult stem 
cells are indispensable for normal tissue homeostasis and repair [46]. The exhaustion of adult 
stem cell pools are the result, for example, of premature senescence and deranged metabolic 
signaling and there is a strong evidence that altered and decreased function of adult stem cells 
has a significant role in the beginning of the aging diseases [47]. Aging also contributes to 
alterations in intercellular communications and the most relevant age-related alteration in 
intercellular communication is “inflammaging”, a smoldering pro-inflammatory phenotype that 
accompanies aging in mammals, involved in age-related diseases [34,48]. 
 
4. PHYSIOLOGICAL AND PREMATURE AGING 
Aging is an inevitable stage of the development and can be classified in two different types: 
the physiological aging (senescence) which refers to intrinsic, progressive and universal changes 
related to advancing age, and the pathological aging (senility) related to modifications which take 
place due to non-normative factors such diseases, brain trauma or poor life habits, independent 
of modifications correlated with healthy aging [49].  
Physiological changes are common to everyone, however their beginning and intensity are 
different. These changes are mainly related with a decrease in metabolic rate, reduction in cell 
counts, reduction of body fluids and tissue atrophy [25]. Some researchers compile these 
alterations into three distinct groups: the first group covers the cellular homeostatic mechanisms 
such as corporal temperature and extracellular fluid volumes, the second refers to the decrease in 
the mass of organs and finally the third is correlated with the decline of the functional reserves of 
the body [2]. As a consequence, all these physiological changes may lead to several abnormalities 
in neurologic, cardiopulmonary, immunologic, endocrine and motor functions. Thus, the contact 
with risk factors as alcohol, smoking, obesity, hypertension, dyslipidemia and stress may lead to a 
wide range of diseases such as neurodegenerative diseases, heart failure, atherosclerosis, 
arrhythmias, osteoporosis, diabetes, infections and tumors [25]. 
The pathological and non-pathological aging is caused by physiological and environment 
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changes, which often compromise life quality. However, aging may also be triggered by genetic 
mutations which lead to some known diseases such as Progeria, Werner, Bloom, Cockayne and 
Rothmund-Thomson syndromes and Fanconi anemia, which can be an ideal model for 
understanding age-related genetic alterations [42]. These patients develop characteristics of 
accelerated aging due to mutations in a couple of genes implied in genetic stability. Clinically 
these syndromes mostly involve premature senescence (huge risk of cancer, atherosclerosis, gray 
hair), metabolic disorders (hyperlipidemia, diabetes), skin changes (hyperkeratosis, atrophy, ulcer) 
and senile dementia [42]. 
 
5. BIOLOGICAL PREDICTORS OF AGING  
The search of specific biological predictors of aging is a challenge for scientists. The main 
goals of identifying biomarkers of aging are related to the comprehension of the mechanisms 
involved in the process, determinate the rate of aging in an individual, observing the impact of 
interventions, like exercise or food restriction in the aging process and estimate lifespan by 
determinate the biological age [50]. 
A biomarker can be defined as a characteristic that can be objectively measured and 
evaluated as an indicator of a physiological as well as a pathological process or pharmacological 
response to a therapeutic intervention [39]. Molecular biomarkers can be classified into three 
categories: those that control the development of the diseases, those that identify the effect of 
the medicines and those which are defined as surrogate endpoints in clinical trials [39]. A 
surrogate marker serves to monitor and diagnose the progression of the diseases [51] and the 
surrogate endpoints predict the effects of therapeutic interventions and are a substitute of clinical 
endpoints [39].  
The term “aging biomarker” appeared for the first time in gerontology and geriatry in the 
early 1980s [52]. An aging biomarker is described as a biological parameter that will envisage the 
functional competence in advanced age [50]. Baker & Sprott refer an AB as a biological parameter 
of an organism that either alone or in some multivariate composite will, in the absence of disease, 
predict the functional capacity at some later age [53,54]. Many researchers tend to assume that 
an age-related change in a biological factor is considered an AB. Nonetheless, for a biological 
parameter be considered an AB it is necessary to distinguish it from a modification indirectly allied 
with age. Differentiate age biomarkers of disease biomarkers is not an easy process, so there are 
some specific criteria for it, which are different depending on the scientist who wrote them 
[50,52–55]. 
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Many factors are directly affected and changed over aging process and a few markers are 
being used to predict biological aging [56]. These predictors might be used to identify people at 
huge risk of developing an age-associated disease or disability. Determination of biological age 
has acquired significance in several subjects such cardiology, neurology or transplant medicine, as 
it can be a powerful indicator to estimate the quality of tissues and organs [54].  
Various putative AB have appeared in the past few decades. Table 1 shows some biological 
predictors of aging identified until now, which are regularly used as AB in population-based 
studies and applied in a variety of settings capable of differentiating amongst healthy and 
unhealthy aging in elderly [7,57]. As it is possible to see in table 1, there are several parameters 
able to characterize and quantify vital functions prone to decline during aging. The molecular 
predictors of aging are associated to the domains of physiological, endocrine, immune and 
inflammatory functions, nervous system and molecular mechanisms [57,58]. The majority of 
these parameters are frequently part of routine medical examinations and for this reason they are 
reasonably easy to measure [59].  
The molecular changes which disturb the function of organs, tissues and cells related to 
physiological function are a remarkable group of biomarkers candidates. To assess lung function it 
is important to measure FEV1 (forced expiratory volume in 1 second) [60], VO2max (maximum 
volume of oxygen) [61] and PEF (peak expiratory flow) [62], which are three important biomarkers 
of pulmonary health. In cardiovascular function the biomarkers that allow to assess the risk of 
coronary heart disease are systolic blood pressure (SBP) [63], diastolic blood pressure (DBP) [64], 
pulse pressure [65], resting pulse rate [66], total homocysteine (tHcy) [67] and electrocardiogram 
[68]. To evaluate bone health and body composition it is essential estimate the bone mass, bone 
density [69], muscle mass [70] and body mass index (BMI) [71]. To assess glucose metabolism it is 
important to quantify the fasting glucose [72] and the glycosylated hemoglobin (HbA1c) [73]. On 
the other hand to assess other metabolic processes it is crucial to assess the following biomarkers: 
low density lipoprotein (LDL) [74], very low density lipoprotein (VLDL) [74], leptin [75] and 
adiponectin [76].  
Biological predictors of aging related to endocrine function are grouped in three different 
categories: HPA-axis (hypothalamic–pituitary–adrenal axis) markers, which are 
dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA) [77,78], cortisol [79] 
and DHEA-S:cortisol ratio [80]; markers of sex hormones, which are E2 (estradiol), FSH (follicle-
stimulating hormone), LH (luteinizing hormone) [81] and testosterone [82] and the marker of 
growth hormones which is IGF-1 (free insulin-like growth factor-1) [83]. These markers are all 
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associated to higher risk of premature mortality and physical frailty. 
The changes in immune system in elderly are associated with alterations in B cells [84], T cells 
[85] and white blood cell count (WBC) [86]. In what concerns inflammatory response, age-related 
modifications are mainly associated with changes in the levels of C-reactive protein (CRP) [87], 
interleukin-6 (IL-6) [88], tumor necrosis factor-α (TNF-α) [89], fibrinogen [90] and albumin [91], 
which are considered AB. 
In nervous system biological predictors of aging are distributed in two different groups: the 
markers of central nervous system (CNS), which are amyloid β42 (Aβ42) [92], total Tau (t-Tau) 
[93,94], phosphorylated Tau (pTau) [95] and F2-isoprostanes [96], linked also to Alzheimer’s 
disease, and the markers of sympathetic nervous system (SNS) which are norepinephrine 
(noradrenaline) [97] and epinephrine (adrenaline) [98].  
The domain with more identified AB to date is the molecular mechanisms domain. According 
to the senescent theories of aging there are a lot of molecular mechanisms of aging. Relatively to 
oxidative stress, the accepted markers are reactive oxidative species (ROS) [99], superoxide 
dismutase (SOD) [100], 8-hydroxy-2-deoxyguanosine [101], 8-isoprostane [102], glutathione [103], 
serum Hsp70 [104] and tyrosine [105]. Concerning genomic instability mechanisms, the accepted 
biomarkers are chromosome structural aberrations levels [106], DNA repair activity [107,108], 
p16INK4A expression level [109], p21 expression level [110], p53 expression level [111], p53-binding 
protein 1 level [112] and number of deletions in mitochondrial DNA [113]. The biomarkers of 
senescence are the levels of senescence-associated β-galactosidase [114], apoptosis levels [115], 
number of senescent cells [116] and Ink4a/Arf ratio [117]. Concerning epigenetic alterations, the 
number of γ-H2AX foci [118], trimethylated lysines at the 27 and 9 positions of histone H3 
[119,120] and senescence-associated heterochromatin foci [121] are considered AB. Relatively to 
telomere attrition the established AB are telomere length [122] and telomerase activity [123]. 
Finally shape of nuclear lamina [124], progerin level [125] and wound healing rate [126,127] are 
other markers related with the molecular mechanisms of aging (table 1).  
 
5.1. Stages of AB Development  
The identification of new biomarkers is required to improve the diagnosis, guide the target 
molecular therapy and observe the therapeutic response in an extensive range of diseases. For 
instance, proteomic methods based on mass spectrometry (MS) ensure the development of new 
biomarkers which potentiates the development of new blood tests. Therefore, advances in 
technology enabled the conception of a biomarker pipeline usually assessed in a series of 
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preclinical and clinical phases [128,129] (figure 2). Plasma is a good candidate for the 
development of new biomarkers as it may reflects the pathological and physiological processes 
that are underway in the entire body [129,130]. In proteomic-based methods the targets for 
biomarker discovery are thousands of proteins/peptides that are typically quantified and 
compared between normal and illness state. Nevertheless, biomarker detection is not actually the 
issue, the problem is in the verification and validation of these putative biomarkers [128–131]. 
Another way to select an aging biomarker is establish a correlation among putative biomarkers 
and the chronological age and telomere restriction fragments [128,132,133]. The next step in 
biomarker discovery is verification, which is essential to recognize biomarkers to proceed to 
clinical validation. In this phase, putative biomarkers are evaluated for changes triggered by 
biological, environmental and/or genetic factors [133,134]. The last step is validation, where the 
samples are examined for biomarker specificity and sensitivity, as well as its standardization 
potential, before further clinical evaluation and use in clinical routine. This phase is one of the 
hardest steps in AB development because it is hard to predict if a molecule is really an indicator of 
the aging status. However, there are also some factors that limit healthspan that difficult 
biomarker validation, such as frailty, which is defined as an age-related clinical syndrome that 
entails loss of resilience and failure to recover from acute problems (e.g. pneumonia, stroke and 
fractures). Therefore there are four important requirements in the validation of an AB candidate: 
(i) evidence better predictive power than chronological age, (ii) give information about the age 
range, (iii) establish specificity and sensitivity and (iv) analyze and minimize methodological 
discrepancies amongst laboratories [133–135]. 
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Table 1 - Briefly summary of the main biological predictors of aging. 
 
Biological Predictors of Aging 
 
 
Subdomain 
 
Biomarker 
 
Health indication Related 
pathologies 
 
How to measure 
 
References 
 
Domain: Biomarkers of Physiological Function 
 
Lung Function 
Forced expiratory volume 
in 1 second (FEV1) 
From age 25 years, FEV1 
declines around 
25ml/year in woman 
and 32 ml/year in men. 
Several studies 
documented that there 
is an inverse association 
among mortality and 
FEV1. 
Mortality, CVD, 
Pulmonary 
diseases 
Spirometry exam 
Measures FEV1. 
[60] 
VO2max (maximum volume 
of oxygen) 
10% of VO2max declines 
per decade in woman 
and men. 
Mortality, CVD, 
Pulmonary 
diseases 
Spirometry exam 
VO2max measures 
the functional 
limit of 
cardiovascular 
system being 
described as index 
of 
cardiorespiratory 
fitness. 
[61] 
Peak expiratory flow (PEF) 
Indicator of airway 
limitation. 
Asthma, COPD 
Spirometry exam 
Measures the 
airway 
obstruction. 
[62] 
Cardiovascular 
Function 
 
Systolic blood pressure 
(SBP) 
The highest arterial 
blood pressure in an 
artery which occurs 
when the heart is 
pumping blood for body. 
Stroke, CHD, 
Mortality 
Physical exam 
Measures heart 
activity. 
[63] 
Diastolic blood pressure 
(DBP) 
The lowest arterial blood 
pressure which occurs 
when the heart is 
resting. 
Stroke, CHD, 
Mortality 
Physical exam 
Measures heart 
activity. 
[64] 
Pulse pressure 
Indicator of augmented 
arterial stiffness. 
Stroke, CHD, 
MI, Mortality 
Physical exam 
Measures heart 
activity. 
[65] 
Resting pulse rate 
Indicator of heart 
functioning and measure 
of overall fitness. 
CHD, Mortality 
Physical exam 
Measures heart 
activity. 
[66] 
Total homocysteine (tHcy) 
tHcy is an amino acid 
involved in lipid 
metabolism.  
Higher plasma 
homocysteine levels 
might cause toxicity by a 
diversity of mechanisms, 
such as oxidative 
damage, which has been 
related to an enhanced 
rate of aging. 
Cardiovascular, 
Peripheral 
vascular, 
Cerebrovascular 
diseases 
Non-fasting 
plasma using 
reverse-phase 
HPLC with 
isocratic elution 
[67] 
Electrocardiogram 
Indicator of cardiac 
function. 
Stroke, 
Cardiovascular 
risk, Mortality 
Physical exam 
Measures the 
electrical impulses 
in the heart. 
[68] 
Bone Health 
Bone mass 
Bone mass and density 
decrease in men and 
women with age. 
Mortality, 
Fractures, CVD 
Bone 
densitometry 
exam 
[69] 
Bone density 
Body 
Composition 
Muscle mass 
Aging is associated with 
reduced muscle mass, 
Mortality 
Physical exam 
Assesses muscle 
[70] 
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 especially leg muscle 
mass. 
mass. 
Body mass index (BMI) 
Indicator of the 
equilibrium among 
energy intake and 
expenditure besides, it is 
also an indicator of 
malnutrition. BMI is 
positively related with 
prevalent disability. 
Mortality, CVD, 
Diabetes 
mellitus, Stroke 
Physical exam 
Measures the 
body fat based on 
height and 
weight. 
[71] 
Glucose 
Metabolism 
Fasting glucose 
Monitor the quantity of 
sugar in blood. 
Diabetes, CHD, 
Mortality 
Hexokinase 
Method 
[72] 
Glycosylated hemoglobin 
(HbA1c) 
Monitor the quantity of 
sugar linked to 
hemoglobin in 
erythrocytes. 
Diabetes 
HPLC Assay 
Fasting blood 
(plasma) 
[73] 
Low density lipoprotein 
(LDL) 
Makes the 
transportation of 
cholesterol from the 
liver to be integrated in 
cell membrane tissues. 
Stroke, CHD, 
Atherosclerosis 
ELISA using 
immunopurified 
polyclonal 
antibodies Fasting 
blood (plasma) 
[74] 
Very low density 
lipoprotein (VLDL) 
Makes the 
transportation of 
cholesterol, 
phospholipids, 
endogenous 
triglycerides and 
cholesteryl esters. 
Atherosclerosis, 
Coronary artery 
disease 
ELISA using 
immunopurified 
polyclonal 
antibodies. 
Fasting blood 
(plasma) 
[74] 
Leptin 
Is a protein hormone, 
which regulates energy 
expenditure and food 
intake. 
There is a progress of 
central resistance to 
leptin with aging. 
Diabetes 
mellitus, 
Metabolic 
syndrome 
(dyslipidemia, 
hyperglycemia, 
hypertension, 
abdominal 
obesity), 
Atherosclerosis, 
Osteoporosis 
Leptin 
concentrations 
were measured 
with a commercial 
RIA kit 
[75] 
Adiponectin 
Anti-inflammatory 
protein secreted by 
adipocytes and has a 
protective function 
against insulin resistance 
and atherosclerosis. 
Adiponectin increases 
with aging and there is a 
strong association 
among this protein and 
mortality. 
Metabolic 
syndrome 
(dyslipidemia, 
hyperglycemia, 
hypertension), 
MI 
ELISA 
Fasting blood 
(plasma) 
[76] 
 
Domain: Biomarkers of Endocrine Function 
 
HPA-axis 
 
Dehydroepiandrosterone 
sulfate (DHEA-S) 
DHEA is a cortisol 
antagonist and a steroid 
hormone produced from 
cholesterol. DHEA-S is a 
metabolite of DHEA. The 
levels of these adrenal 
steroids decline with 
age.  
AD, Mortality RIA [77,78] 
 
Dehydroepiandrosterone 
(DHEA) 
Cortisol 
Steroid hormone, 
produced by the 
adrenals, which implies 
in body answer to 
physiological stress.  
CVD, Fractures, 
Poor cognitive 
function, 
Mortality 
RIA [79] 
DHEA-S:Cortisol ratio 
The DHEA-S:Cortisol 
ratio is related with 
Mortality 
DHEA-S and 
Cortisol 
[80] 
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cognitive impairment. 
 
determined 
through Coat-A-
Count kit 
Sex-Hormones 
Estradiol (E2) 
FSH (Follicle-stimulating 
hormone) 
LH (Luteinizing hormone) 
Responsible for 
secondary sexual 
characteristics in 
women.  
Mortality RIA [81] 
Testosterone 
Steroid hormone.  
Men senescence is 
characterized by a 
reduction in plasma 
testosterone levels 
Mortality 
GC 
(plasma) 
[82] 
 
 
Growth 
Hormone 
 
Free insulin-like growth 
factor-1 (IGF-1) 
Growth factor, inhibitor 
of apoptosis and controls 
cells growth and 
development. 
CAD, Mortality, 
Osteoarthritis 
RIA [83] 
 
Domain: Biomarkers of Immunity and Inflammation  
 
Immune 
Function 
 
B cells 
Aging is characterized by 
lack of B lymphocytes. In 
elderly it is normal a 
decrease of B cell 
number and diversity 
linked with poor health 
status. 
Lymphoid 
neoplasms 
(chronic 
lymphocytic, 
leukemia, 
multiple 
myeloma) 
Flow Cytometry [84] 
T cells 
T lymphocytes protect 
the organism against 
pathogens. 
CD4:CD8 ratio increases 
very slowly with age and 
this ratio less than 1 
leads to high mortality. 
Mortality, AD, 
Atherosclerosis 
Flow Cytometry [85] 
White blood cell count 
(WBC) 
WBC count is an 
indicator of systemic 
inflammation. 
Augmented WBC count 
predicts cardiovascular 
mortality. 
Mortality, CVD 
Automated Blood 
Cell (Coulter) 
Counter 
[86] 
Inflammatory 
Function 
 
C-reactive protein (CRP) 
Protein which is related 
with inflammation. CRP 
levels are increased in 
the brains of AD 
patients.  
Stroke, CVD, 
Heart attack, 
Arthritis, 
Dementia 
Immuno-
turbidimetric 
Assay 
[87] 
Interleukin-6 (IL-6) 
Cytokine that answers to 
acute diseases.  
Strong predictor of 
mortality and immune 
aging illnesses. The IL-6 
levels are higher in older 
people. 
CVD, AD, 
Immune 
disorders, 
Diabetes 
mellitus 
RIA [88] 
Tumor necrosis factor-α 
(TNF-α) 
Pro-inflammatory 
cytokine that has a 
crucial role in the 
pathogenesis of chronic 
inflammatory diseases. 
Diabetes, 
Arthritis, Stroke, 
Obesity, 
Atherosclerosis 
ELISA [89] 
Fibrinogen 
Protein involved in 
coagulation process. 
Mortality, 
CVD, AD 
Clauss Method, 
kinetic Fibrinogen 
Assay 
[90] 
Albumin 
The main protein 
produced by the liver 
which aids maintains 
osmotic pressure and 
does the transport of 
small molecules for 
blood. Lower serum 
albumin levels are often 
present in elderly. 
Heart attack, 
Stroke 
Quantification 
using Gornall, 
Bardwill and 
David Method 
[91] 
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Domain: Biomarkers of Nervous System 
 
Central 
Nervous 
System (CNS) 
 
Amyloid β42 (Aβ42) 
One of the constituents 
of the senile plaques. 
Secretases cleaved the 
Aβ from the large 
amyloid-precursor 
protein (APP) and in 
amyloidogenic pathways 
yields a 42 amino acid 
peptide that can 
aggregate in the brain.  
Amyloid β peptide is 
responsible too for 
oxidative damage. 
AD, 
Frontotemporal 
dementia 
 
ELISA [92] 
Total Tau (t-Tau) 
A component of 
neurofibrillary tangles. 
Total tau levels are 
considerably higher in 
AD and 
Creutzfeldt‐Jakob 
disease patients. 
AD, Creutzfeldt- 
Jakob disease 
ELISA [93,94] 
Phosphorylated Tau (pTau) 
Tau is 
hyperphosphorylated in 
AD, which the 
consequence is a lack of 
function and axonal 
transport dysfunction. 
The presence of tau 
phosphorylated at 
position -181 is 
expressively increased in 
AD. 
Phosphorylated forms of 
tau (phospho-tau -181,   
-199, -231, -235, -396 
and -404) may give 
important progresses in 
early diagnosis of AD. 
 
AD, MI 
Immuno-
precipitation, 
Immunoblotting 
[95] 
F2-isoprostanes (F2-IsoP) 
Isomer of prostaglandins 
(PG) resultant from 
oxygen radical 
peroxidation of 
arachidonic acid 
esterified in membranes 
of the cells.  
Enhanced levels of 8-
isoprostaglandin F2α   (8-
iso-PGF2α) are described 
in AD brain and amyloid-
peptide stimulates the 
production of 8-iso-
PGF2α. 
AD, 
Atherosclerosis 
plaque, High 
cholesterol 
levels 
Isotope Dilution 
(Free F2-IsoP in 1 
to 2 ml of CSF), 
GC/NICIMS 
[96] 
Sympathetic 
Nervous 
System (SNS) 
Norepinephrine 
(noradrenaline) 
Norepinephrine is a 
catecholamine with 
multiple functions as a 
hormone and a 
neurotransmitter. 
Indicator of stress 
answer. 
Synthesized from 
dopamine 
Mortality 
CHF, MI, 
Tritiated (-)-
Noradrenaline 
Analysis 
[97] 
Epinephrine (adrenaline) 
Hormone secreted by 
adrenal medulla. 
Strong emotions like 
anger or fear lead to the 
release of epinephrine in 
the bloodstream, 
Cognitive 
decline, MI 
Isotope Dilution 
(radiolabeled 
epinephrine) 
[98] 
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causing an increase in 
heart rate, muscle 
strength, blood pressure, 
and sugar metabolism - 
“flight or fight response” 
– which prepare the 
body for strenuous 
activity. 
 
Domain: Biomarkers of Molecular Mechanisms 
 
Oxidative 
Stress 
 
Reactive oxidative 
species (ROS) 
Increases during 
lifespan. Causes enzyme 
inactivation, 
deterioration of 
membranes and altered 
cellular function. 
Parkinson’s 
disease, 
DNA damage 
ESR Spectroscopy [99] 
Superoxide dismutase 
(SOD) 
Antioxidant functions in 
cells which are exposed 
to oxygen. 
Inverse relation 
to AD, 
Hypertension 
Enzymatic Assay 
according to 
Marklund and 
Marklund 
Method  
[100] 
8-hydroxy-2-
deoxyguanosine (8-OHdG) 
Oxidative damage of 
nucleic acid.  
The major product of 
DNA oxidation. 
Elderly have higher 
levels of 8-OHdG 
AD, Arthritis, 
Atherosclerosis, 
Cataracts, 
Hypertension, 
Osteoporosis, 
Type II diabetes 
Urinary Enzyme-
Linked 
Immunosorbent 
Assay  
[101] 
8-Isoprostane 
Phospholipid oxidative 
damage. 
8-Isoprostane is 
produced by non-
enzymatic oxidation of 
arachidonic acid present 
in phospholipid 
membranes.  
Higher concentration 
levels are present in 
elderly.  
Arthritis, 
Cataracts, 
Hypertension, 
Type II diabetes 
Enzyme 
Immunoassay 
[102] 
Glutathione (GSH) 
Decreases with aging 
and in some ARD. GSH 
has the function to 
protect the cells from 
oxidative stress. 
AD 
Enzymatic Assay 
in brain 
[103] 
Serum Hsp70 (Hsp – heat 
shock proteins) 
Hsp70 declines in 
elderly. 
AD, Parkinson’s 
disease, 
Huntington’s 
disease, Ataxias, 
Amyotrophic 
lateral sclerosis 
ELISA [104] 
Tyrosine 
Protein oxidative 
damage. 
Tyrosine is created from 
phenylalanine. The 
attack of ROS on 
phenylalanine form o-
tyrosine and m-tyrosine. 
Elderly have decreased 
levels of o-tyrosine. 
Cataracts, 
Type II diabetes 
LC 
(serum) 
[105] 
 
 
 
 
Genomic 
Instability 
 
 
 
Chromosome structural 
aberrations levels 
During aging occurs a 
significant accumulation 
of genetic damages, 
mainly deletions, 
translocations and 
chromatid breaks. 
Several diseases 
Cytogenetic 
Analysis 
[106] 
DNA repair activity 
Mechanism to correct 
chemical damages and 
breaks in the DNA, this 
Several diseases Enzymatic Assay 
[107] 
Reviewed 
in [108] 
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process is realized by 
specific enzyme systems. 
DNA repair decreases 
with aging. 
p16
INK4A
 expression level 
Protein involved in the 
cell cycle control. The 
cell cycle arrest can 
leads to senescence, 
apoptosis or turns 
normal cells in a cancer 
cells. p16
INK4A 
expression 
can promote aging and 
prevent cancer. 
 
Several diseases 
Flow Cytometry, 
Western Blotting, 
Immuno-
histochemistry in 
lymphocytes 
[109] 
p21 expression level 
Inhibits the cyclin-
dependent kinase. Has 
an important role in DNA 
damage answer and 
regulates the cell cycle. 
p21 is an effector of the 
functions of p53 which 
promotes senescence. 
p21 has a dual role in 
aging, since it can 
promote or prevent 
aging.  
Several diseases 
Western Blotting,  
qRT-PCR 
[110] 
p53 expression level 
Transcription factor 
which controls the cell 
cycle. Is involved in 
repair process and DNA 
damage identification. 
p53 is tumor suppressor 
and is noticeable in 
aging cells. 
Several diseases 
Western Blotting, 
qRT-PCR 
[111] 
Level p53-binding  
protein 1 (53BP1) 
53BP1 binds to p53 
protein implied in DNA 
damage response. The 
manifestation of an 
increase in 53ВР1 foci is 
a dependable biomarker 
of aging. 
Several diseases 
Immuno-
fluorescence, 
FISH, TEM 
[112] 
Number of deletions in 
mitochondrial DNA 
 
With the age the 
number of mitochondria 
reduces due to their 
diminished proliferation 
and death, caused by 
mutation in mtDNA. 
Several diseases qPCR, Dot Blot [113] 
Senescence 
 
Level of senescence-
associated  
β-galactosidase 
(SA-β-gal) 
SA-β-gal accumulates 
over the aging process 
and its activity is 
enhanced in old cells. 
Several diseases 
Histochemical 
Analysis of brain 
and Cytochemical 
Analysis of 
hippocampal 
neurons  
[114] 
Apoptosis levels under the 
impact of hydrogen 
peroxide 
Fibroblasts of aged 
animals present higher 
levels of apoptosis after 
damage with reactive 
oxygen species than 
young animals. 
Several diseases Flow Cytometry 
Reviewed 
in [115] 
Number of senescent cells 
Cells that lose their 
proliferative capacity. 
The agglomeration of 
some quantity of 
senescent cells is enough 
to beginning the aging 
process in the tissues, 
organs or in the entire 
organism. 
Several diseases 
Immuno-
fluorescence, 
Immuno-FISH 
[116] 
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Ink4a/Arf 
The Ink4a/Arf locus 
codifies two tumor 
suppressor molecules, 
Arf and p16
INK4a
, the 
main mediators of 
senescence in cells. 
p16
INK4a
 and Arf 
increase in the majority 
tissues with aging. 
Several diseases qRT-PCR [117] 
Epigenetic 
Alterations 
 
γ-H2AX foci number 
y-H2AX is an indicator of 
conformational 
chromatin changes and 
double-strand-breaks in 
DNA. High quantity of y-
H2AX foci is observed in 
nuclei of aging cells. 
Several diseases 
Immuno-
histochemistry 
[118] 
Trimethylated lysine at the 
27 position of histone H3 
(H3K27me3) 
DNA methylation levels 
are diminished in aging 
cells. H3K27me3 levels 
decrease with age and in 
accelerating aging 
processes. 
Several diseases 
Western Blotting, 
Immuno-
histochemistry 
[119] 
Trimethylated lysine at the 
9 position of histone H3 
(H3K9me3) 
Is a marker of 
constitutive chromatin 
and their levels decrease 
with aging and in 
premature aging 
processes. 
Several diseases 
Immuno-
fluorescence, 
Immunoblotting, 
FISH 
[120] 
Number of senescence-
associated 
heterochromatin foci 
(SAHF) 
Domain of facultative 
heterochromatin. Its 
formation happens with 
aging and their 
mechanism describes 
the irreversibility of the 
cell cycle arrest in aging. 
Several diseases 
Immuno-
fluorescence, 
FISH 
[121] 
Telomere 
Attrition 
 
Telomere length 
Telomeres become 
smaller at each cell 
division. Telomere 
length is responsible for 
several age- associated 
diseases. 
Several diseases Immuno-FISH [122] 
Telomerase activity 
Enzyme that extends the 
ends of telomeres. The 
number of cell divisions 
is directly dependent of 
telomerase. Telomerase 
activity decreases during 
aging 
Several diseases RT-PCR [123] 
Others 
Shape of nuclear lamina 
Basis of the nuclear 
membrane. 
Cells with uncommon 
form of the nuclei 
accumulate during aging. 
Several diseases 
Immuno-
fluorescence 
[124] 
Progerin level 
During aging there is an 
accumulation of 
progerin. 
Several diseases qRT-PCR [125] 
Wound healing rate 
Mechanism of damage 
repair of tissues. Wound 
heal is more sluggish as 
we age. 
Several diseases 
Mathematical 
method 
[126] 
 
AD: Alzheimer’s disease; CAD: coronary artery disease; CHD: coronary heart disease; CHF: congestive heart failure; COPD: chronic 
obstructive pulmonary disease; CSF: cerebrospinal fluid; CVD: cardiovascular disease; ELISA: enzyme-linked immunosorbent assay; ESR: 
electron spin resonance spectroscopy; FISH: fluorescence in situ hybridization; GC: gas chromatography; GC/NICIMS: gas 
chromatography/negative ion chemical ionization mass spectrometry; HPLC: high performance liquid chromatography; LC: liquid 
chromatography; MI: myocardial infarct; qPCR: quantitative polymerase chain reaction; qRT-PCR: quantitative real-time polymerase 
chain reaction; RIA: radioimmunoassay, RT-PCR: real time polymerase chain reaction and TEM: transmission electron microscopy. 
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6. THE POWER OF -OMICS IN THE STUDY OF AGING 
Aging research needs multi and transdisciplinary methods using novel high throughput 
technologies that are persistently in development, enhancing exponentially the biological 
information about aging process and clarifying uncharted mechanisms [56]. Ideally, a systematic 
approach for biomarker identification will involve multiple technologies to investigate the aging 
process at all levels. Thus, for a complete approach of aging, an "-omics" approach is needed. 
Genomics is used to identify relevant disease genes, aberrant cellular signaling pathways, and 
expression signatures correlated with aging. Proteomics is used to study protein translation, 
inclusive post-translational modifications and can be used to identify aberrant protein expression. 
Transcriptomics includes the measurement of mRNA levels for quantifying gene expression. And 
finally metabolomics is useful to identify the presence of abnormal levels of small molecule 
metabolites that are specific to and indicative of an underlying aging process [39,136–138]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Different steps of biomarker development. Adapted from [129]. 
 
Biomarker discovery tends to take one of two options: target approach, which is designed to 
investigate a specific molecule or group of molecules and non-targeted approach (metabolic 
profiling and metabolic fingerprinting) designed to analyze a large number of molecules in an 
unbiased manner. Within targeted approaches, commonly used techniques are nuclear magnetic 
resonance (NMR) and magnetic resonance spectroscopy (MRS), multiple mass spectrometry (MS)-
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based methods, and immunoassays (e.g. ELISA). Since there is an increasing trend for biological 
samples to be analyzed without a specific target molecule, within non-targeted approaches 
metabonomics and metabolomics fields have been expanding [139]. 
Metabolite profiling restricts itself to a certain range of compounds or even to screening a 
pre-defined number of members of a compound class. For these two approaches, main 
techniques are gas chromatography (GC), high performance liquid chromatography (HPLC) and 
NMR [140]. Metabolic fingerprinting does not attempt to identify or precisely quantify all the 
metabolites in the sample. Rather, it considers a total profile, or fingerprint, as a unique pattern 
characterizing a snapshot of the metabolism in a particular cell line or tissue. The metabolic 
fingerprinting is very useful in biomarker discovery and diagnostic, namely to discover specific 
metabolic patterns of diseases. 
Mass spectrometry (MS) and Fourier transform infrared (FTIR) spectroscopy are usually used 
in fingerprinting. While MS is often associated with separation techniques (LC, GC or SDS-PAGE) 
FTIR may not require prior separation of the components of the sample [141]. Proteomic 
technologies introduced the concept of a blood signature, arguing that a combination of plasma 
biomarkers (i.e. a signature) rather than a single marker will be needed to reflect the complexity 
of aging [136]. Besides, proteomics has garnered recent attention mainly because proteins are 
readily available in body fluids and are more stable than mRNA and metabolites and because it 
allows to study both structure and function of proteins by several methods, whether qualitative 
or quantitative, allowing to reveal static or perturbation-induced changes in a protein profile 
[142]. Proteomics provides an unbiased approach to detecting protein biomarkers in complex 
sample mixtures such as plasma. It uses MS data coupled with protein database pattern 
recognition search algorithms to identify large numbers of proteins simultaneously. One of the 
most powerful protein identification strategies is liquid chromatography (LC) separation followed 
by MS analysis, usually using ESI (electrospray ionization). Few studies have used proteomic 
methods to discover new AD plasma biomarkers, making neuroproteomics an emerging 
technology. Plasma proteins that have been identified by these techniques are related with lipid 
or other molecules transportation, immune regulation and inflammation [143]. Moreover, it has 
been developed a new field called peptidomics, a proteomic analysis of peptides and small 
proteins, since proteins can be cleaved aberrantly (e.g. APP cleavage by α and β- secretases). So 
direct de novo analysis of endogenous peptides could be invaluable for sample characterization 
and in some cases disease diagnosis [142]. 
Although being still a relatively recent field, metabolomics is being developed and applied as 
21 
 
a more global approach to several age-related disorders biomarkers discovery. Metabolomics is 
now commonly defined as the –omic to detect and quantify all low-molecular-weight molecules 
and metabolites present in cells, tissues or organisms under a set of given conditions. Thus, it is 
able to quantify metabolite changes indicative of alterations in anabolic and catabolic processes in 
the body. In turn, metabonomics is described as the quantitative analysis of metabolic response 
of living systems during pathophysiological stimuli or genetic modification over time [136,137]. 
Metabolomics is typically performed on biofluids, such as serum, plasma, urine, saliva and CSF 
[138]. By assessing hundreds of metabolites simultaneously, metabolomic techniques produce 
high-resolution biochemical snapshots showing the functional endpoints of genetic predisposition 
as well as the sum of all environmental influences such as nutrition and medication. This snapshot 
can provide an almost real-time image of the pathophysiology of an entire organism. This 
information it is not possible to obtain in genomics, proteomics or in other “-omics” [144]. 
Specifically, due to the fact that any biochemical change must precede any morphological 
manifestation of the disease itself, a metabolomic approach may be very useful for early 
diagnosis. It requires analytical techniques of analysis such as chromatography, molecular 
spectroscopy or mass spectrometry, coupled with bioinformatics tools such as multivariate data 
analysis methods to get the most out of the data. Thus, metabolomics information complements 
data obtained from genomics, transcriptomics and proteomics [145]. Metabolomic techniques 
have been used to identify biochemical pathways’ perturbations related to several diseases, 
either in biological fluids (plasma, urine and CSF), animal models and tissue or cell cultures [145]. 
A typical metabolomics study includes four main steps: uniform sample collection, sample analysis 
(e.g. NMR, MS, FTIR), statistical analysis (e.g. PCA, PLS-DA), and identification of significantly 
altered metabolites that could be translated into new disease biomarkers/pathways [146]. The 
main metabolic fingerprinting approaches used for disease diagnostics includes infrared (IR) and 
Raman spectroscopy, NMR and MS-based methods. Hence the multiple advantages and more 
widespread use of infrared (IR) spectroscopy, its role in metabolomics will be emphasized ahead 
[137]. One of the main metabolomics challenges is the development of standard protocols 
regarding sample collection and storage, chemical analyses, data processing, and information 
exchange. Indeed, it was already created the Metabolomics Standard Initiative, with support of 
the Metabolomic Society, to recommend standard protocols for use in all aspects of 
metabolomics research [145]. 
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6.1. Infrared Spectroscopy 
Spectroscopy is increasingly become one of the main tools for biomedical applications and 
has made noteworthy progress in the field of clinical evaluation [147]. The infrared spectroscopy 
is a powerful analytical technique based on the vibrations of the atoms of a molecule. This 
method is one of the most ordinary and used spectroscopic techniques due to its effectiveness in 
provide information about the purity of different compounds and identifying its structures 
allowing knowledge of functional groups, bonding types and molecular conformations [147–149]. 
Nucleic acids, lipids, carbohydrates, the primary and second structure conformation of proteins, 
body fluids, tissues and cell cultures are some of the diverse compounds that can be analyzed by 
IR spectroscopy [147,148]. An infrared spectrum is obtained by IR spectrometer device when the 
infrared radiation (restricted in electromagnetic spectrum between the visible and microwave 
regions – figure 3) crosses through a sample. Each peak of energy present in the absorption 
spectrum matches to the frequency of a vibration of a part of a molecule of the sample. Molecular 
rotations and molecular vibrations are the motions of the atoms in a molecule. The vibrational 
states of the atoms are the responsible for allow infrared radiation absorptions so that the IR 
spectrum is a vibrational spectrum where is possible observe quite sharp bands [148,149]. 
The infrared radiation is subdivided into three different radiation types based on the 
wavelength: near-infrared (NIR) (14000 to 4000 cm-1), mid-infrared (MIR) (4000 to 400 cm-1) and 
far-infrared (FIR) (400 to 4 cm-1) (figure 3). The MIR region is unique for a molecule which 
normally provides information about fingerprint characteristics of molecular species and is 
divided into four regions: X–H stretching region (4000–2500 cm−1), the triple-bond region (2500–
2000 cm−1), the double-bond region (2000–1500 cm−1) and the fingerprint region (1500–600 cm−1) 
[148]. In sum, when the radiation absorbed has equal frequency of the molecular vibration and 
the dipole moment of a molecule is altered due to molecular vibration, IR radiation is absorbed 
leading to the transition of a molecule. The transitions may occur from the v=0, ground vibrational 
state, to v=1, first excited vibrational state (this process is called fundamental tone) or from v=0 to 
v=2, v=3, v=4…, which is a process denominated overtone. In this process, these absorptions are 
weaker than in fundamental tone. Thus, in infrared absorbance spectroscopy we measure the 
quantity of infrared radiation transmitted to a sample in a range of frequencies of 
electromagnetic spectrum, being molecular spectroscopy an evaluation method of the spectra 
formed by the interaction amongst a sample and radiation [149–151]. 
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Figure 3 - The electromagnetic spectrum. 
 
IR spectroscopy is a rapid, non-destructive easy to use tool which allows measurements at 
minimal costs making possible the monitoring of diseases, opening doors for personalized 
medicine [147–149,152]. 
In an IR spectrum the abscissa axis corresponds to the wavelength, wavenumber or 
frequency and the ordinate axis to the absorption intensity (absorbance - A) or to the percentage 
of transmittance (transmittance - T). The main goal for the elaboration of a spectrum is determine 
a signal (S), which represents the amount of radiation absorbed, emitted or reflected by the 
sample. When a signal is obtained is also obtained a noise (N) which may be originated from 
diverse sources. To assess the quality of an IR spectrum the signal-to-noise ratio (SNR) is 
quantified and the quality of the spectrum is greater the higher SNR is [149].  
In general, in spectra analysis, 100% of transmittance corresponds to zero absorption of light 
at that wavelength. Absorbance is mostly used for quantitative work and multivariate analysis 
while the transmittance is commonly used for spectrum interpretation. However, it arises from 
personal preference the choice of which method to use. The wavenumbers and the complexity of 
the peaks in the spectrum provide data about the molecules. The complexity is advantageous due 
to combine an experimental spectrum with a known compound and the frequencies or 
wavenumbers give information about the functional groups existing in the molecule. Therefore 
for the spectra analysis it is essential the help of tables which correlate frequencies with 
functional groups and the theoretical and experimental spectra [148,153,154].  
 
6.1.1. FTIR as a Useful Metabolic Fingerprint Tool 
Since the beginning of 1950s, IR spectroscopy has been an important technique for materials 
analysis in the laboratory. Fourier Transform Infrared (FTIR) spectroscopy is now the main method 
of IR spectroscopy, available for routine work in laboratories.  
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FTIR is a technique almost universal because many molecules have strong absorbances in the 
mid-infrared region, and is applicable for many types of samples (solids, liquids, gases and pasts). 
It is highly versatile, since is needed minimum sample preparation. Infrared spectra are rich in 
information, wherein peaks positions give the information about the structure of molecules in a 
sample. The intensity of peaks is related to the concentration of molecules and peak widths are 
sensitive to the chemical matrix of the sample (pH and hydrogen bonding).  
Given that FTIR spectroscopy is a technique based on metabolomics, it is able to detect 
biochemical changes caused by pathologies, even at a very early stage of the disease. In addition, 
comparing with other laboratory instruments (e.g. for NMR, GC-MS or LC-MS) infrared 
spectrometer is relatively inexpensive [155]. It gives the opportunity to analyze, in real time, small 
amount of sample, providing reliable and reproducible spectral data [156]. Whilst it is not as 
specific and sensitive as other techniques of metabolomics such as GC/TOF-MS, it has been 
recognized as a valuable tool for metabolic fingerprinting, owning to its simplicity and ability to 
analyze several biomolecules simultaneously [157]. 
FTIR can enhance speed collecting a scan each second, it is a precise measurement method 
which does not need external calibration and has highly sensitivity and specificity [158,159]. This 
new approach of spectroscopy has valuable applications in several fields of biomedical research 
and in specific aging research and can be productively applied to samples from a huge variety of 
cell lines, blood cells and tissues. The outcomes of many research studies have concluded that 
FTIR together with the use of proper statistical data analysis techniques has a strong accurateness 
in identifying and classifying chemical and pathophysiological changes in aging and the different 
biomolecules in successful and unsuccessful aging, providing a rapid and non-invasive diagnostic 
test [147,160]. Although FTIR has been recognized as not as specific and sensitive as some of the 
MS-based techniques, the rapidity and reproducibility of FTIR is demonstrable through the 
extensive number of published research using this technology. Besides, it has been recognized as 
a valuable tool for metabolic fingerprinting as it is able to analyze carbohydrates, amino acids, 
fatty acids, lipids, proteins, nucleic acids and polysaccharides simultaneously with a minimum 
amount of sample preparation. Indeed, besides its rapidity (<10 seconds per sample is readily 
achievable), FTIR is an ideal candidate technology for high-throughput screening as it is possible to 
measure thousands of samples per day and obtain information-rich spectra using only 0,5μL of 
sample. Also, FTIR is less expensive and more accurate rather other methods [137,161]. 
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6.1.2. Potential of the FTIR in Diagnosis of Age-Related Diseases 
FTIR has been applied to samples of human tissue and body fluids and has shown potential to 
support clinical pathology, i.e. detecting and grading of disease [162,163]. In this context FTIR 
spectroscopy proved to have potential in cancer diagnosis [150,164,165] such as cervical cancer 
[166], colorectal cancer [167], liver cancer [168], prostate cancer [169,170] and breast cancer 
[171]. The diagnosis and evaluation of the chemotherapeutic efficacy of patients with leukemia 
was also achieved with this technique [172,173]. Others applications include diagnosing arthritic 
disorders [174,175] and determination of kidney complex stones composition [176,177]. Infrared 
spectroscopy has also proved to be a valuable tool for characterizing and differentiating microbial 
cells [178], proving a rapid method for identifying microorganisms responsible for human 
infections [179]. In addition, FTIR has proved to be very useful to understand the mechanism of 
atherosclerosis development [180,181] and the diabetes diagnosis [182,183]. FTIR has been used 
in several pathology research fields besides neurodegenerative diseases [184]. With particular 
relevance, FTIR spectroscopy is used in various studies and in diagnosis of aging-related diseases 
such as the study of protein misfolding and aggregation in Alzheimer’s, Parkinson’s and 
Huntington’s diseases and in prion disease Creutzfeldt–Jakob [185]. FTIR is called the green 
analytical method and is used to quantify the levels of choline (nutrient) and its metabolite 
betaine, which are metabolic associated to trans-methylation pathways including synthesis of 
total homocysteine, a risk factor of CVD [186]. In atherosclerosis, FTIR is used to discriminate 
biochemically and structurally the different depositions of atherosclerotic plaques [187]. In the 
context of diabetes, FTIR spectroscopy has been currently used in research studies however it has 
not yet been applied in clinical practice. Notwithstanding the crucial aim is to quantify the levels 
of HbA1c to allow the screening and assessment of diabetes in patients [188]. Relatively to 
arthritis FTIR is used to distinguish healthy and osteoarthritic cartilages [189]. In the future, it is 
expected that FTIR, in association with other spectroscopic methods, will continue to be used in 
order to conduce to a better comprehension, diagnosis and treatment of aging and aging-related 
diseases [185]. 
 
7. CONCLUSION 
The aging population is the source of huge challenges to healthcare provision and treatment 
of ARD. The study of aging biomarkers might help to comprehend in a molecular dimension the 
aging physiology. Ideally, biomarkers of aging should assess the biological process of aging and 
not the presence of ARD. Regrettably, elderly population typically presents several co-morbidities 
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that challenging the identification of precise biomarkers and it is impossible to study a human 
being during their entire lifespan in order to detect biomolecules that arise and are specific of 
aging. Therefore, aging biomarkers are urgently necessary to evaluate the health state of aged 
people and the potential therapeutic interventions. In the study of aging and age-related diseases, 
it is essential to use reliable methodology of analysis that reflects the changes occurring during 
the aging process and that can differentiate healthy elderly people from elderly people with age-
related diseases and clarify which biomolecules give an aged condition, using peripheral fluids and 
implying reduced costs.  
The absorption of radiation in the mid-infrared spectral region provides itemized information 
on the chemical composition of biological samples and, such the majority of molecular species 
absorbs infrared light, giving rise to distinctive spectral patterns in transmitted light, it is possible 
to use FTIR as a potential method to study the physiological and pathological conditions which are 
related with homeostatic alterations of cells and tissues. This technique allows identifying aging-
related signals at a biochemical level, helping to identify specific biomarkers. Plasma is a reliable 
biofluid for metabolic studies containing numerous biomarkers that can be studied by FTIR. The 
FTIR spectral acquisition and multivariate analysis will help to confirm biomarkers previously 
identified through FTIR spectroscopic assignment and possible discovery and develop novel aging 
biomarkers, helping to better understand the aging process and metabolic aging physiological 
modifications.  
 
8. SIGNIFICANCE OF THE STUDY 
Aging is an unavoidable physiological alteration occurring in organisms over time. Ultimately, 
it leads to death due to successive dysfunctions in every organs of the organism. [25]. Aging is a 
critical risk factor for several human diseases like neurodegenerative and metabolic diseases and 
many types of cancer which have become much more prevalent in the elderly. It is a fact that 
world’s population is aging. In order to improve healthspan of elderly and increase lifespan there 
are a greater need to understand the mechanisms associated with aging process. It is known that, 
many of the neurodegenerative diseases are related with protein aggregates. However, the major 
question which is: what is the relationship between protein aggregates and physiological aging? 
With advancing age there is a loss of proteostasis, being one of the nine hallmarks of aging. In an 
attempt to understand the correlation between aging, protein changes and the presence of 
protein aggregates several studies have been developed.  
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The main goals of this study are:  
1 Evaluate the ability of FTIR to identify protein aggregates/alteration in protein 
conformation in cell models (yeasts); 
2 Correlate aging with the presence of protein aggregates/alteration in protein 
conformation in human plasma samples; 
3 Contribute to the identification of biological predictors of aging particular the presence 
of protein aggregates/alteration in protein conformation by FTIR. 
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Chapter Two 
This chapter gives an overview of Fourier Transform Infrared spectroscopy 
principles and of FTIR equipment and functioning, as well as sample characterization and 
a description of the methods used in this study. 
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2. FTIR METHOD OVERVIEW 
2.1. Fundamental Principles 
Fourier Transform Infrared spectroscopy is a technique that can be applied to a wide range of 
samples and it is based on the analysis of the interaction of IR light with a substance. FTIR 
spectroscopy constitutes the absorption measurement of different IR frequencies by a sample 
positioned in the path of an IR beam. Some of this radiation is absorbed by the sample, due to the 
vibrations of chemical bonds of the molecules, and some of it is transmitted. The resulting 
spectrum represents the molecular absorption and transmission, creating a molecular fingerprint 
of the analyzed sample. In an IR spectrum it is possible to identify sample’s functional groups 
and/or elucidate its molecular structure (qualitative analysis) through the absorption peaks, 
besides, the size of these peaks are directly related with the quantity of each functional group 
(quantitative analysis). FTIR spectrometers are used for acquisition of infrared spectra and these 
devices are able to analyze different types of samples such as solids, liquids and gases [148,190]. 
 
2.2. Molecular Vibrations 
The molecules are not static, when they interact with radiation they oscillate/vibrate. The 
energy possessed by a molecule at any moment is defined as the sum of vibrational energy which 
corresponds to the absorption of energy by a molecule as atoms vibrate about the mean center of 
their chemical bonds; translational energy, which is correlated to the molecules displacement in 
space as a function of the normal thermal motions of matter; electronic energy, which is linked to 
energy transitions of electrons as they are distributed in the molecule and rotational energy, the 
tumbling motion of a molecule being the result of energy absorption within the microwave region 
[191]. The IR radiation does not has enough energy to induce electronic transitions as ultraviolet 
(UV) radiation, thus the absorption of IR is limited to compounds with small energy differences in 
the rotational and vibrational states. When a molecule interacts with infrared radiation there will 
be changes in molecular dipoles associated with rotations and vibrations, the larger the dipole 
change, the stronger the band intensity in IR spectrum [148,192,193]. 
A molecule in its resting stable energy state has a number of freedom degrees which 
represents the potential to change position in space. N is the number of atoms in a molecule, so a 
molecule containing N atoms has 3N degrees of freedom which corresponds to motions along any 
Cartesian coordinates axes (x, y, z). So, each atom has three degrees of freedom and polyatomic 
molecules of N atoms have 3N total degrees of freedom. Nonetheless, three degrees of freedom 
are necessary to describe translational, and other three correspond to rotation of the whole 
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molecule. Thus, polyatomic non-linear molecules have 3N-6 degrees of freedom (three 
translational and three rotational) and polyatomic linear molecules have 3N-5 degrees of freedom 
(three translational and two rotational). The remaining 3N-6 and 3N-5 correspond to fundamental 
vibrations [194].  
The atomic positions in molecules are not fixed, once they are subject to several vibrations 
related with changes in bond angle or bond length. The main types of molecular vibrations (figure 
4) are stretching (axial deformation): change in inter-atomic distance along bond axis, which 
presents two different types: symmetric stretching and asymmetric stretching (asymmetric 
stretching happen at higher frequencies than symmetric stretching) and bending (angular 
deformation): change in angle between two bonds, which has four distinct types: rocking, 
scissoring, wagging and twisting. Bending vibrations take place at inferior frequencies than 
stretching vibrations [148,192,193]. 
 
 
Figure 4 - The different vibrational modes of molecules, divided on stretching type and bending type (in-
plane and out-of-plane) Adapted from [148]. 
 
Isolate the motion of two atoms in one molecule from the motion of the rest of the atoms in 
a molecule is not conceivable. One atom might be mutually shared by two distinct oscillating 
bonds and when this occurs it is designated that the vibrations of the two bonds are coupled. So, 
vibrational coupling is influenced by several factors: strong coupling of stretching vibrations 
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happens when there is a common atom among two vibrating bonds; bending vibrations coupling 
occurs if there is a common bond between vibrating groups; coupling between bending vibration 
and stretching vibration occurs if the stretching bond of one side of an angle varies by bending 
vibration; when coupled groups have roughly equal energies the coupling is greatest; there is no 
coupling amongst groups separated by two or more bonds [192,193]. 
 
2.3. FTIR Spectrometers  
Nowadays, Fourier Transform Infrared spectrometers (figure 5) are largely used and have 
improved the acquisition of IR spectra. Its basic components are: the radiation source, the 
interferometer (predominantly Michelson interferometers), the sample, the detector and a 
computer to process the data. FTIR spectroscopy is based on the idea of the interference of 
radiation among two beams to create an interferogram, which is a signal produced in function of 
the alteration of the path length between the two beams. The two domains of frequency and 
distance are interconvertible by the mathematical method of Fourier Transform (FT) [148].  
The IR radiation is emitted from the source and passes through an interferometer to the 
sample before getting the detector. The interferometer has in its center a semi-reflecting film, the 
beamsplitter, which bisects the planes of the two mirrors presents. The Michelson 
interferometers are constituted by two perpendicularly plane mirrors, one of them is a fixed flat 
mirror and the other one is a moving flat mirror which allows moving this mirror a very short 
distance away from the beamsplitter. Whenever a parallel beam of radiation passes through an 
ideal beamsplitter 50% of the incident radiation will be reflected to one of the mirrors whilst the 
remaining 50% will be transmitted to the other mirror. Thereafter the radiation reflected from the 
mirrors returns to the beamsplitter to recombine and interfere. Through the beamsplitter is 
transmitted 50% of the beam reflected from the fixed mirror already the other 50% is reflected 
back in the direction of the source. The moving mirror in the interferometer generates an optical 
path difference among the two arms of the interferometer and it produces constructive 
interferences, in the case of the reflected beam, and destructive interferences, in the case of the 
transmitted beam. The subsequent interference pattern is designated an interferogram.  
As the interferogram is measured, all frequencies are measured simultaneously, resulting in 
an extremely fast IR measurement so this interferogram signal cannot be interpreted directly, 
since it is necessary a frequency spectrum (a plot of the intensity at each individual frequency). 
Thus, the FT method, performed by a computer, will “decode” the individual frequencies, 
converting the interferogram in an infrared single beam spectrum and the number of peaks 
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present will represent the number of detectable constituents of the sample. It is also essential 
measure a background spectrum, since it is required to has a relative scale for absorption 
intensity [148,150,190]. 
 
Figure 5 - Schematic representation of Fourier Transform spectrometer and its main components. Adapted 
from [148]. 
 
2.4. Attenuated Total Reflectance (ATR) Spectroscopy 
The reflectance techniques might be used for samples that are complicated to analyze 
through the conventional transmittance methods. Attenuated Total Reflectance (ATR) technique 
revolutionized solid and liquid FTIR analysis once it tries to solve the most important challenging 
aspects of IR analysis: sample preparation and spectral acquisition. ATR spectroscopy provides 
faster sampling, improves sample-to-sample reproducibility and minimizes user to user spectral 
variation [148,195].  
ATR uses the phenomenon of total internal reflection, so ATR device measures the changes in 
a totally internally reflected IR beam when the beam comes in contact with a sample. The beam 
of radiation entering in the ATR crystal will undergo total internal reflection when the angle of 
incidence at the interface among the sample and crystal is greater than the critical angle. This 
internal reflectance originates an evanescent wave which will be attenuated or altered in regions 
of IR spectrum where the sample absorbs energy. The resultant attenuated radiation is measured 
and plotted as a function of wavelength through the spectrometer and gives rise to the 
absorption spectral characteristics of the sample [148,194,195].  
ATR spectroscopy is a technique with a lot of advantages, once requires little or no sample 
preparation for the majority of the samples, improves spectral acquisition and reproducibility 
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leading to higher quality in database building, more precise material identification and verification 
and is considered one of the most versatile sampling techniques [194,195]. 
 
2.5. FITR Advantages 
FTIR instruments have several advantages over the traditional dispersive technique including: 
 Increased speed: all frequencies are measured simultaneously (Felgett advantage); 
 Improved sensitivity: once the detectors are considerably more sensitive and the optical 
throughput is greater resulting in much lower noise levels (Jacquinot advantage); 
 Faster scans allow the co-addition of many scans in order to reduce the random 
measurement noise to any desired level (signal averaging); 
 Mechanically simple: since it contains only a moving part, the interferometer moving 
mirror is the unique continuously moving part in the FTIR device; 
 Internally calibrated: FTIR instruments employ a HeNe laser as an internal wavelength 
calibration standard (Connes advantage) becoming self-calibrating. So this technique 
provides a precise measurement which no requires external calibration; 
 Non-destructive technique [190]. 
The choice of this technique in this work is related with the fact that has low costs 
associated, is a non-destructive technique and the sample analysis is very fast allowing having the 
results in a short period of time. 
 
3. METHODS OF STUDY 
3.1. Sample Collection 
Human plasma is commonly used in biological and clinical studies. To acquire it, it is 
necessary to add an anticoagulant such as EDTA (ethylenediamine tetraacetic acid) or heparin in 
the blood collected samples, following by removal of blood cells [196]. Optimizations were 
performed in the sample collection method in order to obtain samples with high quality and 
quantity and to overcome water signals overlap in IR spectra. Since water is the most abundant 
compound of all biological fluids and has a strong absorption in MIR region this becomes a 
problem when FTIR is used. In order to avoid water spectral signals drying process was used [197]. 
In the present study, plasma aliquots of the samples were obtained using K2EDTA tubes (5 
mL) with gel separator and then it was applied a centrifugal force of 1800g during 15 minutes at 
4ºC, in which the blood cells were separated from plasma. Were performed plasma aliquots of 
30µL for the present study which were stored at - 80ºC. 
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3.2. Characterization of Human Plasma Samples 
The inclusion criteria for the present study group were: age over 65 years, resident in Aveiro, 
with no comorbidities or memory impairment. The exclusion criteria include individuals which 
were undergoing radiotherapy or chemotherapy, suffering from psychiatric illness (e.g. 
schizophrenia, bipolar disease) or using illicit drugs. 
To evaluate the cognitive status of the selected individuals was carried out at several centers 
for primary health cares from Aveiro region the following cognitive tests: CDR (clinical dementia 
rating scale), MMSE (mini-mental state examination) and GDS (geriatric depression scale). This 
final test allowed the exclusion from the study of depressed individuals. 
A project to distinguish Alzheimer’s disease patients from control patients (with no AD) was 
approved by the ethics committee of the Regional Health Centre – Coimbra, protocol number 012 
804 of April 4, 2012. However in this present study only the control samples of the approved 
project were used, presenting negative results for all cognitive tests (CDR -; MMSE -; GDS -) (table 
2). 
 
Table 2 - Characterization of the study samples according to gender, age and results of cognitive tests. 
COD Sex Age MMSE CDR 
C1 F 65 - - 
C2 F 65 - - 
C3 F 65 - - 
C4 F 75 - - 
C5 F 75 - - 
C6 F 75 - - 
C7 M 74 - - 
C8 M 78 - - 
C9 M 82 - - 
C10 M 82 - - 
 
 
3.3. Experimental Procedure for Yeasts 
The strains of Saccharomyces cerevisiae used in this study were kindly provided by RNA 
Biology laboratory of iBiMED – Institute of Biomedicine, University of Aveiro (Manuel Santos and 
Joana Tavares).  
We used two different strains: a wild-type strain and a knockout of a specific tRNA modifying 
enzyme, which causes extensive protein aggregation. Protein aggregation was measured by 
fluorescence microscopy since all strains have a fluorescent molecular sensor that allows seeing 
foci of aggregated proteins in the cell. The percentage of protein aggregation in wild-type strains 
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range between 1.18% and 1.26% and in the mutant, the percentage of protein aggregation is 
9.39% and 18.44%. 
 
3.4. Spectroscopy Procedure 
To acquire the spectra it was used MIR spectroscopy. The plasma and yeast samples were 
placed in the ATR crystal of FTIR spectrometer. Mid-IR absorbance spectroscopy plots the 
recorded intensity of absorption bands versus an interval of wavenumbers [150].  
 
3.4.1. Spectral Acquisition 
Previously spectroscopic analysis, the plasma samples that were stored at - 80ºC were 
thawed at room temperature and homogenized with vortex for approximately 8 seconds. Perkin-
Elmer Spectrum BX FT-IRTM spectrometer was used to obtained spectra in the 4000-900 cm-1 range 
at 8 cm-1 resolution with 64 co-added scans. The room temperature and humidity during all 
process were maintained at ± 23ºC and ± 35%, respectively and the spectra were only obtained 
when these room conditions were fulfilled. The acquisition of background single beam was 
performed against air (empty crystal), before 8µL of plasma were placed on the ATR diamond 
crystal. 16 consecutive spectra were acquired, which corresponds to approximately 40 minutes 
being this the estimated time for drying process. Despite time consuming in this process it 
requires minor computational manipulations and is capable of eliminating the water spectral 
contribution, keeping an acceptable SNR [197]. In what concerns to yeast samples, they were 
withdrawn from the culture medium with a swab and placed directly in the crystal. Spectra 
acquisition was performed without drying. Before placed the yeast samples in the ATR diamond 
crystal it was acquired the background spectra against air (empty crystal). 
The spectra were acquired by mid-infrared spectroscopy for each sample and between the 
spectral acquisitions of each sample, the diamond crystal of spectrometer must be carefully 
cleaned with 70% ethanol and distilled water and dried with absorbent paper. Afterward spectra 
acquisition, the data were submitted to multivariate analysis which allows the identification of 
pertinent spectra regions/bands and their corresponding assignment to chemical functional 
groups. 
 
3.5. Multivariate Analysis 
MIR spectroscopy provides rich spectral information that cannot be interpreted by a unique 
visual inspection or single peak analysis. Therefore, it is indispensable to apply appropriate 
multivariate data analysis techniques to support data interpretation. Multivariate data analysis 
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uses mathematical, statistical and computer sciences to efficiently extract useful information from 
data generated via chemical measurements [198]. The results of FTIR, as it was expected, 
provided many variables (wavenumbers) for a given a number of individuals. 
Multivariate analysis methods are divided in multivariate classification (pattern recognition) 
and multivariate regression. Besides that, the pattern recognition techniques can be further 
divided in supervised or unsupervised learning procedures. The linear discriminant analysis (LDA) 
and artificial neural networks (ANNS) are supervised methods once a priori information is 
available regarding the data sets. Whilst in unsupervised pattern recognition, no a priori 
knowledge about the data set is required. Principal-component analysis (PCA) and cluster analysis 
(CA) are examples of unsupervised methods (these are exploratory methods for data analysis). On 
the other hand, the supervised pattern-recognition techniques allow a more precise classification 
within the class boundaries. Multivariate regression methods, like principal components 
regression (PCR) and partial least squares regression (PLS) are often applied to analyze one or 
multiple constituents in a complex sample that are subject to significantly overlapping analytical 
signals [148,151,198].  
In this work, PCA and PLS were applied to the FTIR spectra. PCA is a data-reduction 
technique, once condense the large number of initial variables to a data set with only a few 
variables or principal components (PCs) reflecting the most relevant analytical information. Other 
characteristic of this technique is the effort in resolving overlapping spectral features [150,198]. 
The PCA results comprise two different plots: scores and loadings. The score plot is a projection of 
data onto subspace and it is used for interpreting relations between observations. The loading 
plot is a plot of the relationship among original variables and subspace dimensions and it is used 
for interpreting associations between variables [199]. PLS is a method for making predictive 
models when the factors are many and extremely collinear. This technique condenses the x data 
(variables matching to the frequency or wavelength axis of a spectrum) into less variables and at 
the same time includes the understanding of the y data (variables having the concentration 
information on multiple constituents per sample) along the transformation of the coordinate 
system into so-called factors, which are equal to PCs in PCA [198,200]. PCA and PLS were applied 
to the mid-IR spectra of yeast and plasma samples to specific spectral region 1800-1350 cm-1, 
which is mostly related to protein conformation and to chemical properties of nucleic acids bases, 
fatty acids and carbohydrates, in order to extract the major sources of variability [197]. 
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Chapter Three 
 This chapter contains the results of the application of FTIR spectroscopy to the 
plasma and yeast samples.  
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3. RESULTS AND DISCCUSSION 
3.1. Yeast Samples Spectral Analysis 
With the goal of studying protein aggregates and protein alterations by FTIR, a model 
organism it was used. 
Some physiologic and pathologic mechanisms, as aging, have an universal character and they 
are conserved in a wide range of organisms. The main model systems used to study human 
mechanisms are human cells; Saccharomyces cerevisiae; Caenorhabditis elegans, Drosophila 
melanogaster, Mus musculus and Rattus norvegicus. To study aging these organisms are required 
since in humans aging process it is almost impossible to follow because it is a slow process. Once 
these organisms have small size, short life cycles and are easy to manipulate genetically they 
become inexpensive subjects for studies. In this study Saccharomyces cerevisiae was used. It is an 
extensively used model of cellular and organismal aging [201–204].  
The yeast samples used in this study can be divided in two different groups: wild-type and 
stress, in this last protein aggregation was induced. 
The acquired spectra were subject of direct analysis with visualization of the spectroscopic 
signals related to biochemical pattern of all yeast samples. Once each spectroscopic signal is 
linked to a defined chemical group and/or chemical family of compound it is possible to identify 
and compare the main differences between the two yeast groups: wild-type and stress (figure 6). 
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Figure 6 - The 4000-600 cm-1 FTIR spectral region of yeast samples divided into two different groups: wild-
type (green lines) and stress (black lines) presenting the maximum wavenumber peaks. (B) Picture is a 
magnification of the 1800-900 cm
-1
 and (C) of the 1800-1350 cm
-1
. X-axis: wavenumber (cm
-1
); Y-axis: 
arbitrary units (A.U.) 
(A) 
(B) 
(C) 
43 
 
As known, the spectral region 3500-2700 cm-1 is related to lipids presence (saturated or 
unsaturated), most fatty acids and phospholipids and also some information of amide A and B of 
proteins may be observed in this region. 1800-1350 cm-1 region is related with protein 
conformation mode, being this the region with more study interest and 1200-900 cm-1 region is 
assigned to nucleic acids and polysaccharides. According to figure 6 (C) the maximum 
wavenumber peaks identified in the 1800-1350 cm-1 region are 1640 cm-1, 1546 cm-1, 1454 cm-1, 
1410 cm-1. In accordance to literature the assignment of some bands commonly found in 
microbial FTIR spectra are for 1640 cm-1 amide I of β-pleated sheet structures of proteins 
[205,206], for 1546 cm-1 amide II α-helix band of proteins [163,205–209], for 1454 cm-1 scissoring 
of CH2/CH3 [208,210] and for 1410 cm
-1 C-O-H in-plane bending in carbohydrates, DNA/RNA 
backbone and proteins [205]. According to figure 6, which represents the spectroscopic profile of 
yeasts, there are not differences identified through the direct spectra analysis between the two 
groups of samples in the 1800-1350 cm-1 region (figure 6 (C)). The following step was to apply a 
PCA multivariate analysis to the 1800-1350 cm-1 region for all yeast samples, for a better 
comparison and characterization among the different sample groups. A PLS analysis is also applied 
to the 1800-1350 cm-1 region to investigate the correlation between FTIR spectra and percentage 
of protein aggregates. The region below 1200 cm-1 was not used once the induced stress in the 
models promotes the alteration/production of polysaccharides. 
 
3.2. PCA Analysis and Identification of Main Spectroscopic Differences Between Sample Groups 
Yeasts spectra were submitted to principal components analysis. PCA provides a score and a 
loading diagrams, being possible to identify and characterize the sub-groups of samples: wild-type 
and stress groups. 
 
3.2.1. Spectral Range of 1800-1350 cm-1 
PCA was applied to the 1800-1350 cm-1, specific region of spectra that allow verifying the 
presence of protein alteration in the samples. This spectral range is mostly correlated with protein 
secondary structure (amide I and amide II), even though it can be associated to chemical 
properties of nucleic acids, fatty acids and carbohydrates.  
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Figure 7 - PCA scores of 1800-1350 cm-1 spectral region showing samples distribution at a PC2 x PC3 scores 
diagram. In this diagram it is possible to identify the two different sample groups: wild-type (green) and 
stress (black). gWT: wild-type group, gS: stress group 
 
 
 
 
 
 
 
 
 
Figure 8 - PC2 and PC3 loadings profile of 1800-1350 cm
-1
 region showing the main maximum wavenumber 
peaks. 
 
Through the analysis of figure 7 it is possible verify that the wild-type (gWT) samples are 
located mainly in negative PC3 and the stress (gS) samples are mainly in positive PC3 region. PCA 
loadings allow the comprehension of the distributional pattern of the samples (figure 8) and the 
identification of molecular alterations that might be present. For understand this discrimination it 
is essential the analysis of the assignments of loading signals peaks (table 3 and 4). 
 
 
 
gWT 
Wavenumber (cm-1) 
1685 
1546 
1433 
1399 
1744 
1622 
Lo
ad
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gs
  
1639 1620 
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Table 3 - Assignments of the main maximum peaks from PC2 loadings in the 1800-1350 cm-1 spectral region. 
 
Table 4 - Assignments of the main maximum peaks from PC3 loadings in the 1800-1350 cm
-1
 spectral region. 
Peaks (cm-1) PCs Assignment Score (group) References 
1685 PC3 (+) Amide I band components of proteins gS [163,205,209,210] 
1639 PC3 (+) Amide I band components of proteins gS [163,205,208,209] 
1620 PC3 (+) Amide I band components of proteins gS [163,205,208,209] 
1546 PC3 (-) Amide II band of proteins gWT [163,205–209] 
1433 PC3 (+) C–H bending group in fatty acids gS [214] 
1399 PC3 (-) C=O symmetric stretching of COO
-
 group 
in amino acids, fatty acids 
gWT [163,206–208,210] 
 
According to figure 7 samples’ main distribution occurs along PC3, being the 1685 cm-1, 1639 
cm-1, 1620 cm-1, 1546 cm-1, 1433 cm-1 and 1399 cm-1 maximum wavenumber peaks responsible for 
the discrimination. Although, in this case, these identified peaks are only associated with a sample 
group, gWT or gS, this does not mean that the same peaks are not present in the other sample 
group. 
The peaks at 1685 cm-1, 1639 cm-1 and 1620 cm-1 present in stress samples are related to 
amide I β-sheet structures of proteins, while the 1546 cm-1 band, associated with amide II α-helix 
band of proteins, is observed in wild-type samples. The peak 1620 cm-1 is located in the 
vibrational frequency of an aggregated protein (1620-1625 cm−1) [185,215]. This means that there 
are significant structural differences among gWT and gS in the amides regions.  
As amide I band is sensitive to protein secondary structure, FTIR is commonly applied to study 
protein alterations, mainly protein aggregation and misfolding in vitro, which has been widely 
used to monitor amyloid fibril formation in Escherichia coli samples. FTIR spectroscopy is a well-
established technique, which has been shown to be sensitive to the secondary structure of 
proteins, becoming a valuable technique to assess the presence of protein aggregates in vitro. 
Due to unique hydrogen bonding environments for the diverse secondary structure elements, 
shifts are found in the frequency of the amide I band [185,216–218].  
1433 cm-1 band is found in stress samples and is related with C–H bending in fatty acids and 
the 1399 cm-1 band is associated with C=O symmetric stretching of COO- group in amino acids and 
fatty acids and is present in wild-type samples. This suggests that although the two groups of 
Peaks (cm-1) PCs Assignment Score (group) References 
1744 PC2 (-) Ester C=O stretching of triglycerides, C=O 
stretching of polysaccharides, C=O 
stretching of lipids  
gS [147,211–213] 
1622 PC2 (+) Amide I band components of proteins gWT [163,205,209,210] 
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samples contained fatty acids in their composition they have present differences that FTIR was 
able to detect.  
These preliminary results confirming that protein conformational changes can be detected by 
FTIR and this spectroscopic technique may be used in follow up protein changes related to aging 
process.  
The PCA analysis allowed verifying that there are differences in proteins spectral region (1800-
1350 cm-1) between the wild-type and stress samples. So, in the following step it was applied a 
PLS analysis to all spectroscopic data (represented in figure 6) in the 1800-1350 cm-1 spectral 
region with the goal to study the correlation between FTIR spectra and percentage of protein 
aggregates. 
 
3.3. PLS Analysis to Evaluate the Correlation Between FTIR and Percentage of Protein Aggregates 
Evaluated by Microscopy 
PLS analysis was applied to 1800-1350 cm-1 spectral region in order to predict the correlation 
between FTIR spectra and percentage of protein aggregates in yeast samples (figure 9 (A)). A 
correlation with a determination coefficient of R2=0,65 was observed with a calibration of 4,06% 
RMSEC and a prevision error of 4,52% RMSEP, the model was built with two latent variables, 
meaning that the biggest part of the variation of Y is linearly explained by X (model appropriate).  
This PLS model gives the information about the spectral signals that are correlated to the 
percentage of protein aggregates (figure 9 (B)) that are identified in table 5. The positive peaks 
identified in coefficient B are related to the stress samples, the ones with higher percentage of 
protein aggregates. 
 
 
 
 
 
 
Figure 9 - (A) Correlation between percentages of real values of protein aggregates and predictive ones. (B) 
Coefficient B was obtained with two latent variables. 
 
 
 
 
 
(B) 
(A) 
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Table 5 - Assignments of the identified maximum wavenumber peaks from PLS (1800-1350 cm-1). 
Peaks (cm-1) Coef. B Assignment References 
1789 + C=O stretching affected by Cl, etc. (not clear 
which are biomolecule contributors) 
[205,207] 
1770 + C=O stretching affected by Cl, etc. (not clear 
which are biomolecule contributors) 
[205,207] 
1744 + Ester C=O stretching of triglycerides, C=O 
stretching of polysaccharides, C=O stretching of 
lipids 
[147,211–213] 
1702 + C=O stretching, H-bonded in DNA, RNA [147,205,219] 
1685 + Amide I band components of proteins [163,205,208,209] 
1625 - Amide I band components of proteins [163,205,208,209] 
1549 - Amide II band of proteins [163,205–209] 
1526 - Amide II band of proteins [163,205–209] 
1503 + >CH2 and >CH3 bending modes of lipids and 
proteins 
[178] 
1489 + C-H deformation* [147,220] 
1455 + C-H deformation of >CH2 in lipids, proteins [205,207] 
1418 + C-O-H in-plane bending in carbohydrates, 
DNA/RNA backbone, proteins 
[205] 
*Characteristic band assignments of biological samples. 
 
Proteins in a non-native conformation could engage in aberrant interactions with other 
cellular components and/or aggregate. The misfolded proteins are cytotoxic, so several 
neurodegenerative and age-related disorders are related with misfolding and aggregation. The 
majority of the knowledge on protein aggregation arises from in vitro studies. There are some 
studies on aggregation in living cells. For example, it was already identified around 200 
aggregated proteins in stationary phase Saccharomyces cerevisiae [221–223]. Nevertheless, 
aggregation is not necessarily a dead-end situation for a protein in vivo. It has been observed in 
cells from different species disaggregation followed by refolding of aggregated proteins [223].  
According to figure 9 (B) spectroscopic signals correlated with protein alterations and protein 
aggregation were identified in stress and wild-type samples. The main bands identified in PLS are 
1685 cm-1, 1625 cm-1, 1549 cm-1 and 1526 cm-1. The peak at 1685 cm-1 is related with amide I β-
sheet structures and represents stress samples. The vibrational frequency of an aggregated 
protein falls around 1620–1625 cm−1 [185,215]. In humans it was already verified through FTIR 
that amyloid plaques have elevated β-sheet content, as demonstrated by a strong amide I 
absorbance at 1625 cm-1 in brain tissue samples [215].  
The 1625 cm-1 band, in human brain tissues, is considered a shift in amide I bands due to 
protein aggregates [215]. However, in this study, it is related with wild-type samples with less 
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amount of protein aggregates, being this an opposite result of what was expected to have, once it 
was expectable that 1625 cm-1 band was related with stress samples, samples with high amount 
of protein aggregation. The 1549 cm-1 and 1526 cm-1 bands are related with amide II α-helix 
structures in wild-type samples. So, it is possible claim that the principal differences are in the 
amide I (1700-1600 cm-1) and amide II (1550-1450 cm-1) regions reflecting protein conformational 
changes. Nonetheless, it is necessary to perform additional studies to understand better the 
relationship between the presence of protein aggregates in the samples and the presence of FTIR 
spectroscopic signals, for example by characterization of protein fraction by SDS-PAGE. 
FTIR spectroscopy has shown to be capable of discriminating between wild-type and stress 
yeast samples in the protein region, more concretely in amide I region, reflecting protein 
conformational changes. 
Consequently, FTIR was applied to human plasma samples of volunteers with age between 
65 and 82 years old with the main goal of identify and characterize protein alterations. 
 
3.4. Spectral Analysis of Human Plasma Samples  
The proteins present in the human plasma are a mixture of complement products, 
lipoproteins and other conjugated proteins called “plasma proteins”. The three major fractions of 
plasma proteins are albumin, globulins (α1-globulin, α2-globulin, β-globulin and ¥-globulin) and 
fibrinogen. Serum albumin is the most abundant protein in the mammal’s serum and has a role as 
a molecular chaperone being able to prevent misfolding and/or protein aggregation [224,225]. 
Each one of spectral signals have one or more assignments (specific type of molecular 
vibration), that match to a defined chemical group and/or chemical family compound. This 
correspondence allows the identification of principal chemical components of whole plasma 
samples (table 6). After acquisition, spectra of plasma samples were subject to direct analysis with 
visualization of main spectroscopic signals related to chemical pattern of all plasma samples. 
Figure 10 presents all spectra of elderly plasma samples used in this study.  
The mid-infrared region can be divided in smaller spectral regions of interest where strong 
absorption bands are related with specific components. The regions include: fatty acids region; 
amide region; (primarily to proteins and peptides); mixed region; (ascribed to carboxylic groups of 
proteins); free amino acids and polysaccharides and polysaccharides region. In addition, there are 
other spectral regions like the one which is relevant to RNA, DNA and phospholipid content [200]. 
In the 900-600 cm-1 region some bands arise from aromatic ring vibrations of phenylalanine, 
tyrosine, tryptophan, and various nucleotides [165]. In order to look in detail to the spectroscopic 
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differences associated with age, spectra of plasma of 65 years old donor (newest of the data set) 
was compared with one of 82 years old (oldest of the data set). The identification of major 
differences was identified in figure 11. 
 
 
Figure 10 - FTIR spectra of all plasma samples used in this study, in a wavenumber of 4000-900 cm
-1 
(A). The 
FTIR spectral regions of 1800-900 cm
-1
 (B) and 1800-1350 cm
-1 
(C) were magnified once they had study 
interest. This figure represents the 60 spectra that include the 6 replicates of the 10 samples that comprise 
the data set. X-axis: wavenumber (cm
-1
); Y-axis: arbitrary units (A.U.) 
 
Table 6 - Spectral assignments of plasma samples. 
Peaks 
(cm-1) 
Assignments Plasma Contents References 
≈ 3454 N-H stretching Proteins (amide A) [226] 
≈ 3286 N-H stretching, H-O-H symmetric and 
asymmetric stretching* 
Proteins (amide A) [227,228] 
≈ 3072 C-H stretching Aromatic ring [147,229] 
≈ 2962 C-H asymmetric stretching of CH3 group* Lipid acyl chains in lipid bilayers 
(phospholipids) 
[163,227,230,231] 
≈ 2938 C-H stretching of CH2 and CH3 group* Fatty acids [163,226,227] 
≈ 2872 C-H symmetric stretching of CH3 group Lipids (long chain fatty acids, 
phospholipids) 
[191,232,233] 
≈ 1740 C=O stretching Fatty acids esters (triglycerides), lipid 
bilayers (phospholipids)  
[137,227,234] 
(A) 
(B) 
(C) 
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≈ 1716 C=O stretching  Carbonic acid, phospholipid sub-
structures, purine bases from nucleic 
acids 
[163,227,234,235] 
≈ 1694 C=O stretching in-plane coupled to the C-
N stretching and N-H bond in-plane 
bending  
Proteins (amide I) [147,236] 
≈ 1680 Unordered random coils and turns of 
amide I 
Proteins (amide I) [147,236] 
≈ 1644 - Proteins (amide I) [147,236,237] 
≈ 1636 C=O stretching and N-H in-plane bending Proteins (amide I) [238,239] 
≈ 1570 - Proteins (amide II) [147,236,240] 
≈ 1550 C-N stretching and N-H bending Proteins (amide II) [147,241,242] 
≈ 1536 N-H in-plane bending, C-H stretching* Proteins (amide II) [163,227,228] 
≈ 1516 N-H in-plane bending and C-H stretching Proteins (amide II) [238,239] 
≈ 1512 CC (phenyl ring) stretching; CH in-plane 
bending* 
Tyrosine band (proteins side chain) [163,227,243] 
≈ 1470 CH2 bending; 
C-H asymmetric bending; 
CH2 symmetric in-plane bending 
(scissoring)* 
Proteins; 
Carbohydrates; 
Lipid acyl chains in lipid bilayers 
(phospholipids) 
[147,163,231,234] 
≈ 1452 CH2 bending and CH3 asymmetric in-plane 
bending (rocking)*; 
C-O symmetric stretching 
Proteins, membrane lipids 
(phospholipids); 
Carbohydrates 
[147,230,231,234] 
≈ 1398 C=O symmetric stretching of COO- group; 
C-O symmetric stretching*;  
C-O bending (carboxylate ions)*; 
CH3 and N
+ (CH3)3 symmetric bending* 
Proteins and carbohydrates; 
Mixed region (carboxylic groups); 
Membrane lipids (phospholipids) 
[228,230,231,234] 
≈ 1396 CH3 symmetric bending of the CH3 groups 
of proteins 
Proteins [147,244] 
≈ 1310 - Proteins (amide III) [147,245] 
≈ 1242 N-H in-plane bending, C-N stretching*; 
P=O asymmetric stretching of PO2
- group 
Proteins (amide III, mainly α-helix 
conformation); 
Phosphodiester groups of nuclei 
acids 
[147,227,228] 
≈ 1168 Ester and CO-O-C antisymmetric 
stretching*; 
C-O, C-C stretching and C-O-H, C-O-C 
deformation* 
Membrane lipids (phospholipids);  
Carbohydrates 
[227,228,231] 
≈ 1115 C-O, C-C stretching, C-O-H, C-O-C 
deformation and C-O-C asymmetric 
stretching*; 
P-O-C symmetric stretching, C-O 
stretching of C-OH group 
Carbohydrates; 
Phosphodiesters; 
RNA 
[147,227,234] 
≈ 1077 C-O, C-C stretching, C-O-H, C-O-C 
deformation and C-O-C asymmetric 
stretching*; 
Po2
-, CO-O-C symmetric stretching* 
Carbohydrates; 
Membrane lipids (phospholipids) 
and nucleic acids sugar backbone 
[147,227,231,234] 
≈ 1032 C-O, C-C stretching, C-O-H, C-O-C 
deformation*; 
C-O symmetric stretching 
Carbohydrates; 
Nucleic acids sugar backbone 
[147,227,234] 
≈ 987 C-O; C-C stretching; C-H-O, C-O-C 
deformation, C-H bending*; 
CH3-N asymmetric stretching 
Carbohydrates; 
Membrane lipids (phospholipids 
[227,234] 
≈ 924 C-O; C-C stretching; C-H-O, C-O-C 
deformation*; 
N+(CH3)3 symmetric stretching*  
Carbohydrates; 
Membrane lipids (phospholipids) 
[227,231] 
*Characteristic band assignments of biological samples (not specific for plasma).
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Figure 11 - 4000-900 cm-1 FTIR spectral region of two plasma samples, one of a 65 years donor (blue line) 
and other of a 82 years donor (orange line), presenting maximum wavenumber peaks. (B) Picture is a 
magnification of the 1800-900 cm-1 and (C) of the 1800-1350 cm-1. X-axis: wavenumber (cm-1); Y-axis: 
arbitrary units (A.U.) 
(A) 
(B) 
(C) 
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According to signals observed in spectra (figure 10 and 11) table 6 was created. It provides a 
bibliographic review of the assignments that have been published until now in the infrared 
spectroscopy field about assignments of the mid-IR spectrum associated to biological samples. 
The mid-IR spectroscopy is a great tool for study biological molecules and through this technique 
it is possible identify the following main groups of these molecules: proteins and peptides, lipids, 
carbohydrates and nucleic acids [148,153,184].  
 Infrared spectra of proteins exhibit absorption bands related to their characteristic amide 
groups. There are nine amide bands, amide A, amide B and amides I-VII, however, only amides A, 
I, II and III were identified in this study. Amide A and amide B appear at approximately 3300 cm-1 
and 3100 cm-1, respectively and are due to N-H stretching vibration. Amides I and II are the main 
bands in the protein infrared spectrum, being amide I the most important to study secondary 
structure. Amide I IR bands are located in the region 1700-1600 cm-1. This band represents 70–
85% of C=O stretching vibration of the amide group coupled to in-phase bending of the N–H bond 
and stretching of the C–N bond. Amide II band region shifts from 1550-1450 cm−1 and represents 
40-60% of the N-H bending and 18-40% of the C-N stretching vibrations. Amide III can be located 
at 1250-1300 cm-1 region and its band is the combination of C-N stretching, N–H bending, C=O 
stretching and O=C–N bending. The amides III and IV are very complex bands resulting from 
mixtures of several coordinate displacements. In amides V-VII it is possible to see out-of-plane 
motions. In mid-IR analysis amide IV-VII bands are not of importance and are bands with very low 
intensities [148,153,228]. 
 Lipids are important molecular components of membranes and have characteristic C-H 
stretching vibrations located among 3025-2700 cm-1 region in FTIR spectrum. IR bands due to the 
terminal CH3 functional groups appear at 2957 cm
-1 (asymmetric stretching) and 2872 cm-1 
(symmetric stretching). Triglycerides, phospholipids and cholesteryl esters, present in blood 
serum, are the classes of lipids identified in mid-IR analysis. These classes of compounds can be 
characterized by their carbonyl bands: at 1742 cm−1 for the triglycerides, at 1737 cm−1 for the 
phospholipids and at 1723 cm−1 for the cholesteryl esters representing the peak maxima 
[148,235]. 
 IR bands associated to carbohydrates are related to hydroxyl and carbonyl groups and 
acetal bonds. The carbonyl group bands can be identified at the 1650-1850 cm-1 region which 
corresponds to the C=O stretching vibration. In the 950-750 cm-1 region of mid-IR spectrum it is 
possible to distinguish the correspondent bands for α and β conformers or pyranoid and furanoid 
ring vibrations of monosaccharides and polysaccharides [153,242].  
53 
 
 FTIR spectra give as well information about nucleic acid biochemistry. DNA and RNA bases 
represent the purine and pyrimidine vibrations in 1800-1500 cm-1 region. In addition, the 
following characteristic findings are representative of a FTIR spectra of nucleic acids: C=O 
stretching vibrations from purine and pyrimidine at the wavenumbers 1717 cm-1 and 1666 cm-1 
respectively, and also antisymmetric and symmetric PO2
- stretching vibrations at the region 1500-
1000 cm-1 [148,235]. The detailed description of the spectra, summarized in table 6, helps to 
interpret figure 10 and to explain the differences detected in figure 11. These figures present 
spectra in the 4000-900 cm-1 region.  
In this precise region (figure 10 (C)) one of the main peaks is around 1740 cm-1, which is 
related with C=O stretching in lipids and ester C=O stretching in phospholipids [147,246]. Peak at 
1640 cm-1 is related with amide I β-sheet band of proteins [147,241], 1540 cm-1 is associated with 
amide II absorption [147,236], 1450 cm-1 is related with asymmetric CH3 bending modes of the 
methyl groups of proteins [147,247] and 1400 cm-1 is associated with symmetric stretching 
vibration of COO- group of fatty acids and amino acids and symmetric stretching of CH3 groups in 
proteins [147,248,249]. In order to have a better comparison between samples, making evident 
the most significant differences upon age, spectra of two plasma samples were selected. The 
chosen samples represent the 65 years sample which corresponds to the youngest donor of the 
data set and the 82 years sample corresponds to the oldest donor of the data set. These spectra 
allowed to identify the main protein differences in plasma related to age (figure 11).  
According to figure 11, which represents the spectroscopic profile of plasma of the 65 and 82 
years volunteers, the most significant identified differences are in the regions 1644-1634 cm-1 and 
1570-1518 cm-1. Protein spectra have two major features, amide I (1700-1600 cm-1) and amide II 
(1550-1450 cm-1) bands. Amide I bands assume increase sensitivity to the alteration of protein 
secondary structure. 
The wavenumbers 1644 cm-1 and 1634 cm-1 are associated to amide I and the wavenumbers 
1570 cm-1, 1554 cm-1, 1536 cm-1 and 1518 cm-1 with amide II. These main differences might be due 
to conformational changes in proteins that involve secondary structure of amides. Amide I β-
sheet structures have vibrational frequencies approximately at 1610–1640 cm-1 and/or 1680–
1700 cm-1 and random coil structures around 1640–1650 cm-1 [148,250]. So it is possible to 
assume that 1644 cm-1 represents a random coil and 1634 cm-1 peak a β-sheet [148,250]. In amide 
II random coil, α-helix and turn structures fall around 1504–1525 cm-1, 1527–1560 cm-1 and 1564–
1583 cm-1, respectively [250]. Therefore, the wavenumber 1570 cm-1 represents a turn, 1554 cm-1 
and 1536 cm-1 a α-helix and 1518 cm-1 a random coil [250]. It is Known that β-sheet conformation 
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is more prone to form aggregates [251], so it is possible to conclude that the 1634 cm-1 could be 
related with aggregates.  
 After direct spectral analysis, with the purpose to investigate the correlation between age 
and protein alterations/modifications it was applied a PLS analysis to all spectra of the data set 
(represented in figure 10) in the 1800-1350 cm-1 spectral region, assigned mainly to proteins 
amide I and II. 
 
3.5. PLS Analysis Allows the Correlation Between Age and Protein Alterations 
PLS was applied to 1800-1350 cm-1 spectral region to evaluate the correlation between age 
and proteins spectral region of human plasma samples (figure 12 (A)). A correlation with a 
determination coefficient of R2=0,68 was observed with a calibration of 10,88% RMSEC and a 
prevision error 6,72% RMSEP. The model was built with two latent variables indicating that the 
majority of the variation of Y is linearly explained by X (model appropriate). This PLS provides 
information about the spectral signals that are related to age (figure 12 (B)), which are identified 
and characterized according to its assignments in table 7. The positive peaks of coefficient B are 
related with samples from older volunteers and the negative peaks with younger volunteers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 - (A) Correlation between real values of age and predictive ones. (B) Coefficient B was obtained 
with two latent variables. 
 
Table 7 - Assignments of the major maximum wavenumber peaks from PLS (1800-1350 cm-1). 
Peaks (cm
-1
) Coef. B Assignments  References 
1694 + C=O in-plane stretching coupled to the C-N stretching and N-H bond 
in-plane bending (antiparallel β-sheet amide I) 
[147,236] 
1682 + C=O guanine deformation N-H in-plane;  
Unordered random coils, turns and loops (amide I) 
[147,226,252] 
1664 + C=O band of α-helical structure (amide I)*, turns and loops [226,242] 
1650 + C=O symmetric stretching band of α-helical structure (amide I) [147,227,233] 
1624 - C=O stretching band of parallel β-sheet (amide I) [226,235,252] 
(A) (B) 
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1584 + C=N imidazole ring stretching (nucleic acids);  
Benzene ring vibrations from arginine 
[148] 
1572 + NH3
+ symmetric bending (membrane lipids); 
C=N imidazole ring stretching (nucleic acids) 
[148,230,231] 
1544 - N-H in-plane bending and C-N stretching (amide II) [147,228,233] 
1524 - N-H in-plane bending and C-N stretching (amide II); 
Stretching C=N, C=C 
[147,219,228] 
1510 - N-H in-plane bending and C-N stretching (amide II);  
C-H in-plane bending of phenyl rings (tyrosine) 
[226,243,253] 
1502 + C-H in-plane bending; 
C=C stretching; 
o-Tyr 
[147,254] 
1484 + N+(CH3)3 antisymmetric bending (lipids); 
NH3
+ bending from lysine 
[153,231] 
1468 + CH2 scissoring and CH3 scissoring and asymmetric bending of 
phospholipids (membrane lipids); 
CH2 bending (lipids, proteins); 
CH2 in-plane bending (lipids) 
[147,148,227] 
1454 + Asymmetric CH3 deformation [147,248] 
1432 + CH2 in-plane bending (polysaccharides); 
C–O–H in-plane bending (carboxylic acids) 
[147,148] 
1392 + C=O stretching of COO–; 
CH3 symmetric bending (nucleic acids) 
[228,244] 
*Related to structural analysis of synthetic polypeptides. 
 
Amide I (1700-1600 cm-1) and amide II (1550-1450 cm-1) bands are the two most prominent 
vibrational bands of the protein backbone [238]. The amide I is due to C=O stretching vibration 
and amide II to N-H bending and C-N stretching vibrations. Amide I bands concentrated among 
1650 cm-1 and 1660 cm-1 are usually considered to be characteristic of α-helix structures, bands 
between approximately at 1610-1640 cm-1 and 1680-1700 cm-1 are characteristic of β-sheet 
structures and bands at 1660 cm-1 and 1680 cm-1 are characteristic of turn structures [250,255]. 
1694 cm-1 and 1624 cm-1 spectroscopic signals identified in figure 12 (B) are related to β-sheet 
forms of amide I, the peak 1664 cm-1 are related with a turn and 1650 cm-1 with α-helix. The peak 
at 1682 cm-1 is related with unordered random coils, turns and loops of amide I. The vibrational 
frequency of an aggregated protein falls around 1620-1625 cm−1 [185,215]. The 1624-1630 cm-1 
region in figure 12 (B) belongs to the typical amide I β-structure band of the amorphous 
aggregates [252]. So it is visible through the analysis of table 7 and figure 12 (B) that there are 
many protein conformational differences in the amide I spectral region. It is known that aging is 
characterized by the decline of proteostasis leading to changes in proteins. 
The bands 1584 cm-1 and 1572 cm-1, correlated to the oldest, are probably related to 
alteration in conformational state and structural stability of nucleic acids molecules. In addiction 
1572 cm-1 band is also associated to structural changes in lipids [148,231]. Many data support that 
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the amyloid proteins exhibit a high binding affinity for nucleic acids. Nucleic acids have been 
studied to be capable of inducing and accelerating significantly aggregation of amyloid proteins 
and the binding between nucleic acids and amyloid proteins leads to several variations in 
conformation of these proteins [256]. 
The 1544 cm-1 is related with amide II α-helix and 1524 cm-1 and 1510 cm-1 with amide II 
random coil. These bands are associated with unaltered protein conformation of amide II 
[226,233,250]. The 1510 cm-1 band is also related with free tyrosine which is a common precursor 
of biological amines [230].  
1484 cm-1 and 1468 cm-1 bands positively correlated with the samples of the oldest 
volunteers are related to structural properties of lipids, mainly with membrane lipids such as fatty 
acids and phospholipids being these the principal targets of free radicals, oligomers and other 
damage-inducing agents [147,227,228,231]. Amyloid deposits from many human diseases contain 
membrane lipids. In most amyloid diseases, protein aggregation has been related with membrane 
disruption in cells and in model lipid systems. It has been observed that protein adsorption to lipid 
membranes, and that the lipid membranes intervene with aggregation process. Besides that, 
protein in diverse aggregation states (monomeric, oligomeric or fibrillary) may cause changes in 
membrane permeability and morphology. Furthermore, there is great evidence that lipids have a 
crucial role in the pathology of Parkinson’s disease [257].  
According to figure 12 (B), the 1624 cm-1 band, which represents a β-sheet structure of amide 
I, is located in the vibrational frequency of protein aggregates (1620-1625 cm-1) and is related to 
the newest volunteers. Although, the obtained results are not what were expected since, our 
assumption was that protein aggregation increases with age, we cannot rule out the hypothesis 
that this spectroscopic signal shows a shift in the spectra reflecting conformational changes in the 
1620-1625 cm-1 protein aggregation spectral region. Thus, it is possible to affirm that there is a 
correlation between age and the protein spectrum, suggesting that there are conformational 
changes with age however these need to be studied with greater detail. Relatively to the 
remaining results it is important to emphasize that nucleic acids could be one of the major 
inductors of aggregates and lipids have a crucial role in neurodegenerative diseases associated 
with protein aggregates.  
As organisms age, the balance of gene expression levels, quality control, and protein disposal 
is disturbed. So, aging process leads to an age-related impairment of proteasome structure and 
function, due to protein damages occurring over the aging. Regulation of proteostasis has a 
crucial role in preventing protein aggregation which might be due to a decrease of efficacy with 
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age in the cellular systems responsible for protein degradation, to changes in chaperones levels in 
older and aging is likewise related with higher levels of oxidative stress, leading to irreversible 
oxidation of proteins, which impairs their degradation. These age-dependent alterations in 
protein homeostasis can be responsible to the aberrant aggregation of proteins in 
neurodegeneration and amyloidosis contexts. Aberrant protein aggregation is considered the 
hallmark of a wide range of age-related diseases such as Alzheimer’s Parkinson’s and Huntington’s 
diseases, yet it is still known whether proteins aggregate with age in a non-disease context 
[185,251,258]. Diminished protein solubility and a predisposition to aggregate are observed 
during physiological aging but the causes are currently unknown [259]. 
Protein aggregation is the abnormal combination of misfolded proteins into larger, 
frequently insoluble structures. Aggregation is classified in two different categories: amyloid and 
amorphous. The amorphous protein aggregation is characterized by unordered aggregation of 
proteins, with each individual protein not commonly related with disease when aggregated. 
Amyloid protein aggregation is an extremely structured, insoluble, fibrillary deposit, generally 
consisting of several repeats of the same protein. To safeguard proteostasis, cell have molecular 
chaperones that are capable of detecting non-native misfolded proteins and act upon them to 
avoid amyloid formation and aggregation [260]. FTIR spectroscopy is sensitive to the secondary 
structure of proteins, so it is a potential technique for studying protein aggregation [185]. Many 
studies have been performed to prove that protein aggregates increase with age and indeed 
represent one aging factor [261,262]. 
 
4. CONCLUDING REMARKS 
The interests to study the relationship between aging and protein aggregates and assess the 
capacity of FTIR in identify protein aggregates are growing, once ever more humans want to 
extend and improve lifespan. Most neurodegenerative diseases and other age-related diseases 
are largely associated with protein aggregates, so their study may lead to improvement in disease 
progression. FTIR is a rapid and non-destructive easy to use tool that presents low associated 
costs and it is widely used in studies related with aging and protein aggregates.  
Plasma samples from volunteers with age between 65 and 82 years, with the goal to identify 
main protein conformation differences, through FTIR, were used in this work and were also 
studied in previous works of the research group [184,197,263,264]. Yeast samples, wild-type and 
stress (induced protein aggregation) groups, were also used. Model organisms are extremely 
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important in physiologic and pathologic studies once it is possible in these follow all aging 
process.  
In this work, it was possible to evaluate the ability of FTIR to identify protein 
aggregates/alteration in protein conformation in yeasts, providing that this spectroscopic 
technique combined with adequate multivariate analysis tools, can be a useful screening method 
for posterior metabolomics/proteomic studies interested in follow protein aggregation with 
aging. 
Direct analysis of human plasma spectra allowed identifying the principal chemical FTIR 
assignments in plasma, which is crucial to creating a pattern of chemical vibrations and 
recognizing the principal absorption peaks in the 1800-1350 cm-1 region that could give significant 
information. Since biological samples have great complexity, direct analysis is not sufficient to 
characterize and identify the different samples used in this study and besides that it is also not 
capable of identifying proteins changes and to correlate these with age. So, multivariate data 
analysis techniques were applied to draw out the significant and no redundant information.  
IR spectra can be divided in several regions with important information, for example, the 
3500-2700 cm-1 region represents especially lipids (saturated or unsaturated) particularly fatty 
acids and phospholipids, the 1800-1350 cm-1 region is related with protein conformation allowing 
identifying the protein structures and protein aggregates and the 1200-900 cm-1 region is 
associated to carbohydrates and nucleic acids and also some spectra signals present in this region 
could be associated with membrane lipids. In this work 1800-1350 cm-1 spectral region was 
studied. In this region, where protein signals can be observed, was found the presence of protein 
aggregates and these have preferentially β-sheet structures. Relatively to plasma samples it is 
important consider that the presence of clinical factors could have some impact in the results, for 
example the use of medication capable of disturbing biochemical plasma levels or unknown 
genetic predisposed factors. 
This thesis allowed conclude that FTIR is capable of identifying different changes in the 
proteins spectral region, these structural differences are located predominantly in the amides 
region; mostly in amide I region and the β-sheet structures have greater tendency to be related 
with protein aggregates. It is known that aging leads to loss of proteostasis, so it can be also 
concluded that there is a positive correlation between age and protein alterations. 
As was mentioned above, FTIR spectroscopy analysis has showed to be able in identify the 
protein differences and protein aggregates in different samples. Additional studies and complete 
clinical trials will be required to prove effectively that aging and protein aggregates are directly 
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related and posteriorly it will be possible to contribute with knowledge to design medicines and 
treatments anti-aging.  
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